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Abstract 
An impaired synaptogenesis is known to be a common neuropathology in a number of 
severe mental disorders including schizophrenia, Parkinson disease, bipolar and 
dementia. Protein tyrosine phosphatase 1B (PTP1B) has been reported to impair neurite 
outgrowth and synaptic formation via attenuating Brain-derived neurotrophic factor 
(BDNF)-mediated signalling. Leptin signalling also facilitates BDNF and promotes 
synaptogenesis which is inhibited by PTP1B. Therefore PTP1B is a potential drug target 
to reverse BDNF-mediated neurogenesis. In this study, lupane triterpenes, a cluster of 
natural products, are determined as novel PTP1B allosteric inhibitors which inhibit 
PTP1B with strong potency and selectivity. Lupane triterpenes inhibit psychotomimetic 
drug-induced PTP1B and reverse PTP1B-caused BDNF reduction and neurogenesis 
impairment, indicating that lupane triterpenes are potential drug candidates for PTP1B 
inhibition and PTP1B-related neurological disorders.  
Firstly, lupane triterpenes were identified as novel PTP1B allosteric inhibitors which 
strongly and specifically inhibited PTP1B. In Chapter 2, through computational studies 
including molecular docking and molecular dynamics simulations, lupane triterpenes 
were confirmed to bind to PTP1B allosteric site. Following binding free energy 
calculations were established to characterise the interactions between lupane triterpenes 
structures and PTP1B allosteric binding site, providing evidence for future chemical 
modifications. Moreover, pro-inflammatory factor TNFα stimulated PTP1B level in 
neurons which was, however, inhibited by lupane triterpenes treatments. Considering 
that PTP1B overexpression has been reported to impair BDNF-mediated neurogenesis 
in neurons, it is of interest to investigate whether lupane triterpenes are able to reverse 
PTP1B-mediated BDNF reduction and neurite outgrowth impairment in neurons. 
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Secondly, PTP1B was found to be significantly increased in phencyclidine (PCP)-
treated neurons and caused downstream BDNF reduction and neurogenesis impairment. 
In Chapter 3, the psychotomimetic drug PCP induced PTP1B through blockage of 
NMDA receptor subunit 2B (NR2B). Enhanced PTP1B attenuated BDNF-mediated 
Akt/GSK3β signalling, leading to reduced synaptogenesis. Furthermore, leptin increases 
BDNF expression and promotes synaptogenesis which was also impaired by PCP-
induced PTP1B. PTP1B directly inhibited JAK2 phosphorylation and thus attenuated 
leptin signalling and pSTAT3, leading to reduced BDNF. Importantly, the study showed 
that lupeol, one of the lupane triterpenes, significantly reduced PTP1B expression and 
stimulated BDNF level, restored leptin signalling, BDNF-mediated signalling and 
synaptogenesis. Lupeol also improved the treatment effects of current antipsychotic 
drugs on reversing PCP-induced BDNF alterations, implicating PTP1B inhibition as a 
potential treatment strategy. 
Furthermore, I developed a label-free and high-throughput microfluidic platform based 
on the inertial microfluidic technique to separate neurons and glial cells from dissected 
brain tissue rapidly and continuously (see Chapter 4). The collected neurons and glia 
were confirmed healthy with significantly improved purity. Moreover, PCP reduced 
BDNF level in both separated and unseparated neurons with no significant difference, 
indicating that the device did not change the cell biological properties responding to 
drug treatment. Increasing evidence has shown that neurons and glia both play 
significant roles in the development of neurite outgrowth and synaptic formation. 
Therefore, it will be necessary to investigate the protein alterations, such as PTP1B, in 
both cell types contributing to disease-induced impairment in neurogenesis and 
synaptogenesis. However, it is difficult to differentiate the roles of neurons and glia 
because the methods used to separate and collect neurons and glial cells from brain 
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tissues are ineffective and inefficient. This microfluidic microchip can enrich and purify 
both neurons and glia with unaltered morphology and biological function. We therefore 
anticipate that this microfluidic device will be an outstanding platform for future cell 
culture studies to investigate disease mechanism and perform drug screening.   
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Chapter One 
1.1 Introduction 
Protein Tyrosine Phosphatase 1B (PTP1B) is an intracellular protein which is widely 
expressed in the human body including the brain, liver, muscles, and adipose tissue. 
PTP1B has been found up-regulated in obesity, type 2 diabetes and breast cancer, 
indicating PTP1B is a potential drug target in these diseases (Ukkola and Santaniemi, 
2002, Zabolotny et al., 2008, Yip et al., 2010). Recent studies have revealed a new 
aspect of PTP1B which inhibits BDNF/TrkB signalling and leads to impaired neurite 
outgrowth and synaptic formation, implicating PTP1B as a therapeutic target in 
neurological disorders (Ozek et al., 2014, Krishnan et al., 2015). It is therefore 
necessary to develop PTP1B inhibitors. PTP1B traditional inhibitor is designed to target 
PTP1B active site. It is difficult to achieve inhibition selectivity against PTB1B, 
however, due to the fact that PTP1B active site and surrounding catalytic domains are 
highly similar to other members of the Protein Tyrosine Phosphatase (PTP) family 
(Julien et al., 2011, St-Pierre and Tremblay, 2012). PTP1B allosteric inhibitor was then 
discovered and proposed as an alternative drug design strategy to specifically inhibit 
PTP1B (Wiesmann et al., 2004, Zhang and Zhang, 2007). Therefore it is of interest to 
develop novel PTP1B allosteric inhibitors and investigate their treatment efficacy. 
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1.2 Literature Review 
1.2.1 PTP1B is a recognized drug target for leptin resistance 
Protein tyrosine phosphatase 1B is encoded by gene PTPN1 which is located on human 
chromosome 20q13 (Brown-Shimer et al., 1990), a region identified as closely related 
to obesity (Lembertas et al., 1997, Lee et al., 1999). Numerous epidemiological studies 
have reported PTPN1 single nucleotide polymorphisms (SNPs) associated with 
development of obesity in the worldwide population (Tsou and Bence, 2012). PTP1B is 
ubiquitously expressed in the central nervous system (CNS) (Bence et al., 2006) which 
is known to induce obesity via attenuating leptin signalling (Zabolotny et al., 2002).  
Leptin is a hormonal signal which acts in the brain and controls food intake and energy 
expenditure (Schwartz and Porte, 2005, Morton and Schwartz, 2011). The leptin 
signalling pathway is initialized by the tyrosine phosphorylation of Janus Kinase 2 
(JAK2) which subsequently modulates downstream signals such as the signal transducer 
and activator of transcription 3 (STAT3) (Morris and Rui, 2009) (Fig.1.1). The 
JAK2/STAT3 pathway is strongly linked to significant weight loss and feeding 
inhibitions (Coppari et al., 2009). Phosphorylated STAT3 transports into cell nucleus 
and affects regulation of appetite by affecting the transcription of hypothalamic 
neuropeptides such as neuropeptide Y (NPY), agouti-related protein (AgRP) and 
precursor pro-opiomelanocortin (POMC). NPY and AgRP stimulate food intake and 
decrease energy expenditure as orexigenic factors which are opposite to anorexigenic 
neuropeptide POMC (Schwartz et al., 2000) (Fig.1.1).  
Leptin resistance in the CNS is one of the factors causing obesity. One of the 
contributors to leptin resistance is PTP1B which dephosphorylates JAK2 and thus 
attenuates central leptin signalling (Cheng et al., 2002) (Fig.1.1). Previous studies have 
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revealed that pro-inflammatory factor TNF-α stimulates PTP1B via activating Nuclear 
factor-κB (NF-κB), leading to leptin resistance (Picardi et al., 2010, Yu et al., 2013a) 
(Fig.1.1). Inhibition of neuronal PTP1B is essential to maintain leptin sensitivity as well 
as prevent obesity development (Bence et al., 2006). Neuron-specific deletion of PTP1B 
in mice has shown lower adiposity, enhanced leptin sensitivity, improved energy 
expenditure and has prevented weight gain in animals fed a high-fat diet (Bence et al., 
2006). Moreover, central administration of PTP1B antisense oligonucleotides also 
displays reduced hypothalamic PTP1B expression in a diet-induced obese (DIO) rat 
model, resulting in restored leptin signalling and control of energy balance (Picardi et 
al., 2010). Therefore PTP1B is a drug target for obesity treatment.  
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Figure. 1.1: PTP1B attenuates leptin signalling via blocking the JAK2/STAT3 pathway 
and leads to development of obesity. Leptin signalling is activated via JAK2 
phosphorylation which further regulates pSTAT3 and downstream gene transcription 
including POMC, AgRP and NPY to modulate energy homeostasis. Furthermore, 
PTP1B inhibits BDNF receptor TrkB phosphorylation and therefore attenuates BDNF-
mediated Akt/GSK3β signalling, leading to impaired neurite outgrowth and 
synaptogenesis. TNF-α is a critical pro-inflammatory cytokine activation of NF-κB 
which results in over expression of PTP1B.  
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1.2.2 New aspect of PTP1B: a BDNF signalling blocker in neurological disorders 
As already mentioned, PTP1B has been demonstrated to attenuate leptin signalling 
(Zabolotny et al., 2002). Leptin is not only beneficial to energy homeostasis but also 
plays an important role in promoting synaptogenesis and neurite outgrowth to facilitate 
learning and memory (Bariohay et al., 2005, Komori et al., 2006, Yamada et al., 2011). 
One of previous study has reported that leptin stimulation improves neurite outgrowth 
and synaptogenesis markers in mouse neural cell lines, as well as increasing cell 
proliferation and differentiation to promote hippocampal neurogenesis (Moon et al., 
2013). In in vivo studies, memory deficits and decreased synapse density have been 
observed in leptin or leptin receptor deficient rodents (Li et al., 2002, Bouret et al., 2004, 
Pinto et al., 2004, Farr et al., 2006), such as ob/ob mice, db/db mice and fa/fa rats. 
Importantly, leptin administration increases brain-derived neurotrophic factor (BDNF) 
mRNA in the hypothalamic nucleus and facilitates BDNF expression in hypothalamic 
STAT3-positive neurons (Komori et al., 2006). Numerous studies have revealed that 
BDNF plays an important role in regulating neurite outgrowth, synaptic plasticity and 
cognitive function (Huang and Reichardt, 2001).  
BDNF and its receptor, tropomyosin-related kinase B (TrkB) are highly expressed in a 
number of brain regions. BDNF has a high affinity to bind TrkB receptor on either side 
of the synapse, facilitating both presynaptic release of excitatory neurotransmitters and 
postsynaptic receptor insertion, as well as spine maintenance (Noble et al., 2011). 
Recently, Ozek et al. reported that PTP1B overexpression inhibited BDNF/TrkB 
signalling while inhibition of PTP1B or genetic PTP1B deficiency restored BDNF/TrkB 
signalling and BDNF-mediated neurite outgrowth and BDNF-induced metabolic effects 
(Ozek et al., 2014). Krishnan et al. further demonstrated that PTP1B inhibited tyrosine 
phosphorylation of TrkB to attenuate BDNF signalling in the neurological disorder Rett 
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syndrome model which presents autistic features (Fig.1.1). Pharmacological inhibition 
of PTP1B ameliorated the behaviour test and improved survival in mice models 
(Krishnan et al., 2015).  Increasingly, studies have disclosed the influence of PTP1B on 
neuronal development. Fuentes et al. revealed that PTP1B participated in neuronal 
plasticity formation and reduction of PTP1B level improved dendritic filopodia, 
learning and memory (Fuentes et al., 2012). It is important to note that the reduction of 
BDNF has been reported in a number of mental disorders including schizophrenia 
(Angelucci et al., 2005, Favalli et al., 2012). Therefore it is of great interest to 
investigate the role of PTP1B in modulating BDNF-mediated neurite outgrowth and 
synaptogenesis in schizophrenia-like models.   
1.2.3 Phencyclidine models show BDNF reduction and dysfunction in 
schizophrenia 
Phencyclidine (PCP) is a recognized psychotomimetic drug. PCP is a non-competitive 
and dosage-dependent blocker of the N-methyl-D-aspartate (NMDA)-type glutamate 
receptors, binds equally to NMDA receptor subunit 2A (NR2A) and NMDA receptor 
subunit 2B (NR2B) (Paoletti and Neyton, 2007) and induces psychotic symptoms that 
are similar to schizophrenia in humans and rodents (Javitt and Zukin, 1991, Morris et al., 
2005). Apart from other recognized psychotomimetic drugs including amphetamine, 
PCP is capable of mimicking negative symptoms such as alogia, anhedonia, and social 
withdrawal, as well as cognitive deficits in addition to positive symptoms including 
delusions, hallucinations, and thought disorder in schizophrenia (Andreasen, 1995, 
Jentsch and Roth, 1999). PCP has been reported to induce reduction of neurite 
outgrowth and synaptogenesis. The effects of PCP on reducing dendritic spine density 
and neurite outgrowth have been reported in both in vitro and in vivo studies (Hajszan et 
al., 2006, Adachi et al., 2013). A decreased number of spines in the prefrontal cortex of 
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rats has been confirmed using sub-chronic PCP treatment (Hajszan et al., 2006), 
suggesting that PCP treatment contributes to abnormal synaptic function in 
schizophrenia-related behaviours (Frankle et al., 2003).  
BDNF alteration is widely observed in schizophrenia pathophysiology (Favalli et al., 
2012). Durany et al. observed reduced concentration of BDNF in post-mortem tissue 
collected from patients with schizophrenia, compared to control (Durany et al., 2001). 
Increasing evidence also shows the alteration of BDNF transcriptional level. Weickert et 
al. found a significant decrease of BDNF mRNA, TrkB mRNA and BDNF level in 
schizophrenia patients (Weickert et al., 2003, Weickert et al., 2005). The majority of 
studies have found the reduction of BDNF serum level in first-episode and medication 
naive schizophrenia patients compared to healthy control (Buckley et al., 2007, Chen et 
al., 2009). 
Previous studies have reported that PCP treatment is associated with alteration of BDNF 
protein level and mRNA level. Sub-chronic PCP administration induced severe 
disruption of cognitive performance with reduction of BDNF in various regions of rat 
brains (Snigdha et al., 2011). Other researchers have administered PCP in cultured 
cortical neurons and disclosed decreased BDNF mRNA level (Katanuma et al., 2014). 
A recent study found that PCP treatment for 48 hours reduced the amount of BDNF, 
decreased secretion of BDNF and inactivated Trk receptors in cultured neurons. The 
number of synaptic sites and expression of synaptic proteins were also suppressed, 
together with diminished glutamatergic neurotransmission (Adachi et al., 2013). 
Moreover, PCP suppressed the BDNF-mediated signalling Akt/GSK3β pathway 
(Adachi et al., 2013), which has been shown to regulate synaptogenesis and neurite 
outgrowth (Kitagishi et al., 2012, Smillie et al., 2013) (Fig.1.1). For example, Akt 
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facilitated dendritic spine protein and Akt phosphorylation involved in working memory 
formation (Emamian et al., 2004). GSK3β was expressed abundantly in neurons in the 
developing rat brain to regulate dendrite extension and synapse formation (Leroy and 
Brion, 1999). Therefore, BDNF reduction and dysfunction are responsible for the loss 
of synaptic connections caused by PCP. Since PTP1B inhibits BDNF-mediated 
signalling, it is interesting to investigate the role of PTP1B in PCP models and develop 
potent PTP1B inhibitors to reverse PCP induced alterations. 
1.2.4 Neuregulin-1 (NRG1) and susceptibility to schizophrenia 
A genome-wide scan of diverse schizophrenia populations has provided insight into 
mechanisms of this disorder and revealed several genes, such as neuregulin-1(NRG1), 
to be closely associated with schizophrenia (Stefansson et al., 2002, Harrison and 
Weinberger, 2004). Research on NRG1 and its receptor ErbB4 (v-erb-a erythroblastic 
leukaemia viral oncogene homolog 4) improved our understanding of schizophrenia-
induced impairment of neurodevelopment, neurotransmission and synaptic plasticity 
(Mei and Xiong, 2008). It has been reported that mutant mice, heterozygous for either 
NRG1 or ErbB4, displayed behaviour abnormality, cognitive deficit and reduced 
functional NMDA receptors compared to wild-type mice, which however overlapped 
with mouse models for schizophrenia (Stefansson et al., 2002). Therefore models based 
on NRG1 mutation have been established to explore the implications for the 
pathophysiology of schizophrenia and potential treatments.  
Recent studies have used NRG1-/+ mutant mice to investigate the interactions between 
NRG1 and NMDA receptor (Bjarnadottir et al., 2007, Zhang et al., 2016). NRG1 
signalling has been confirmed to stimulate phosphorylation of Y1472 on the NR2B 
subunit of the NMDA receptor which played a key role regulating channel properties. 
The reduction of NR2B Y1472 phosphorylation was associated with the behavioural 
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abnormalities and altered synaptic plasticity in NRG1 -/+ mutant mice. These results 
indicated that attenuated NRG1/ErbB4 signalling contributed to the psychopathology of 
schizophrenia through the impairment of NMDAR modulation, NR2B in particular. 
1.2.5 Challenges in discovering PTP1B traditional inhibitors: disadvantages of 
targeting PTP1B active site 
Full-length PTP1B (encoded by PTPN1) is 435 amino acids (about 50 kDa) (Chernoff 
et al., 1990), including an N-terminal catalytic domain (the so-called PTP domain) and a 
C-terminal domain which localizes the PTP1B to the endoplasmic reticulum (Frangioni 
et al., 1992) (Fig.1.2a). PTP1B belongs to the Protein Tyrosine Phosphatases (PTPs) 
family, which contains more than 100 members. Most members display a consensus 
catalytic loop signature (H/V)C(X)5R(S/T), the so-called PTP loop or catalytic loop, 
which is normally composed of 8 amino acids from His214 to Arg221 (Barford et al., 
1994), including the active site Cys215 which is conserved and essential for enzyme 
catalysis (Julien et al., 2011, St-Pierre and Tremblay, 2012). PTP1B also contains a PTP 
loop located in a catalytic cleft formed by four other loops. The depth of the catalytic 
cleft contributes to specifically recognizing tyrosine as the substrate (Johnson et al., 
2002).  
As previously mentioned, the PTPs family has many members. One of them is T-cell 
protein tyrosine phosphatase (TCPTP) which is similar in structure to PTP1B. TCPTP 
(encoded by PTPN2) is cloned from a peripheral human T-cell cDNA library (Cool et 
al., 1989). The alternative splicing gives rise to two variants of TCPTP (Fig.1.2a): a 45 
kDa form (TC45) which lacks the hydrophobic C-terminus and targets the nucleus, and 
a 48kDa form (TC48) which localizes to the Endoplasmic reticulum (ER) by the C-
terminus (Tiganis et al., 1999, Tiganis and Bennett, 2007). The amino acid sequence 
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identity between the PTP domains of TCPTP and PTP1B is 74% (Fig.1.2a) with a 
minor difference in four clusters of amino acid residues, and TCPTP shares a strong 
similarity with PTP1B in 3D structure (Fig.1.2b). Additionally, TCPTP has a catalytic 
cleft containing the active site Cys216 and the catalytic efficiencies between TCPTP 
and PTP1B are almost identical based on their catalytic constant (Kcat) and Michaelis 
constant (Km) (Iversen et al., 2002). However TCPTP regulates different biological 
functions despite high structural similarity to PTP1B. PTP1B has been confirmed to 
dephosphorylate JAK2 to attenuate leptin signalling while TCPTP dephosphorylated 
JAK1 and JAK3 to regulate the immune system (Simoncic et al., 2002), suggesting that 
TCPTP may have little influence on mediating central leptin signalling. In an addition, 
entirely TCPTP knock-out mice showed damage in their immune system such as 
haematopoiesis defects (You-Ten et al., 1997).  
The active site plays as an essential role in PTP1B catalysis which processes as a two-
step mechanism. In the first step, the sulphur atom of Cys215 begins a nucleophilic 
attack on the phosphate on the tyrosine, and then Asp181 acts as a general acid to 
protonate the tyrosyl-leaving group of the substrate. An intermediate cysteinyl-
phosphate is therefore formed (Tonks, 2003). In the second step, the phosphate is 
released from the intermediate by hydrolysis, mediated by Gln262 and Asp181. 
Traditional PTP1B inhibitor design targets the active site Cys215 and most active-site 
targeted inhibitors are non-hydrolyzable pTyr mimetics (Zhang and Zhang, 2007). The 
traditional inhibitors target both active site residues and neighbouring residues, so called 
subpockets which are adjacent to the PTP active site to increase the inhibition 
selectivity (Zhang, 2002). However considering PTP1B and TCPTP share a very similar 
active site loop and surrounding loops (Iversen et al., 2002), it is doubtful whether the 
selectivity of active-site targeted drugs, PTP1B traditional inhibitors in other words, 
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inhibit PTP1B over TCPTP. On the other hand, PTP1B traditional inhibitors are pTyr 
mimetics which generally display high charge density, making it difficult to penetrate 
cell membranes, leading to poor bioavailability. Therefore, the novel drug discovery is 
targeting the allosteric site of PTP1B which inhibits PTP1B activity by affecting the 
movement of WPD (Residues 179-181, Trp-Pro-Asp) loop in PTP1B (Wiesmann et al., 
2004). 
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Figure. 1.2: This picture represents the strong similarity of structure in the PTP domain 
between TCPTP and PTP1B. They have 74% identity in sequence (a) and strong 
similarity in the 3D structure (b). Due to the conservative catalytic domains, it is 
difficult to develop selective PTP1B inhibitors which specifically target PTP1B (PDB 
code: 1PTY) over TCPTP (PDB code: 1L8K).  
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1.2.6 Developing PTP1B allosteric inhibitors is an alternative strategy 
The WPD (Residues 179-181, Trp-Pro-Asp) loop is an important feature in the catalysis 
of PTP1B (Barr, 2010). Under physiological conditions, protein can exhibit multiple 
conformations and sometimes involve large-scale conformational transitions (so-called 
allosteric transition) in contrast to the usual static view brought by a single structure. 
This is nicely illustrated by the movement of the WPD loop in PTP1B captured by X-
ray crystallography. During the transition of the WPD loop in catalysis, PTP1B 
expresses two different conformations, open and closed (Fig.1.3c). In the open model 
(PDB Entry 2HNP), the WPD loop forms an open binding crevice which allows active 
site access to reach the tyrosine substrate and in the closed conformation (PDB Entry 
1SUG), the WPD loop closes over the cleft where the active site forms an intermediate 
with the phosphate, sequestering the cysteinyl-phosphate intermediate and one 
nucleophilic water molecule (Pannifer et al., 1998), finally, phosphoryl transfer from the 
intermediate to the buried water molecular occurs and the WPD loop re-opens the cleft 
to continue catalysis. The conformation difference provides a new design of PTP1B 
inhibitors called PTP1B allosteric inhibitors. Allosteric inhibition aims to prevent WPD 
movement from open mode to closed mode and results in the inactivity of PTP1B. In 
2004, the PTP1B allosteric site was identified, sited 20 Å away from the catalytic pocket 
(Wiesmann et al., 2004) (Fig.1.3a). The high-resolution crystal structures of PTP1B in 
complex with allosteric inhibitors including compound 2 and compound 3 (Fig.1.4), 
revealed that instead of targeting the enzymatic active site, these inhibitors bond to an 
allosteric site composed by 3, 6 and 7 (Wiesmann et al., 2004) (Fig.1.3b). It has 
been proposed that through long-range coupling these allosteric inhibitors can prevent 
the closure of the WPD loop and thus the formation of the active state of the enzyme. In 
this way, the inhibitors locked PTP1B in a catalytically incompetent state. It is 
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encouraging that the allosteric inhibitors showed high potency in inhibiting PTP1B 
while at the same time having significant selectivity over TCPTP. Allosteric inhibitors 
have advantage over other inhibitors, which target the active site, since key residues 
involved in the allosteric binding are not conserved in most PTPs (Zhang and Zhang, 
2007). Interestingly, this allosteric inhibition strategy has also been applied to target 
SHP2, which is another member of the PTPs family, showing a potent, selective and 
orally efficacious inhibition (Chen et al., 2016, Garcia Fortanet et al., 2016). Therefore, 
allosteric inhibition is an ideal treatment strategy in PTPs inhibition including PTP1B. 
Considering only a few selective PTP1B inhibitors with acceptable pharmacological 
properties are under clinical trials, such as TransTech Pharma Inc TTP814, and Ohr 
Pharmaceutical Inc Trodusquemine (MSI-1436) (Krishnan et al., 2014), which are in 
Phase II and Phase I testing, respectively (Osherovich, 2011), it is necessary to develop 
novel PTP1B allosteric inhibitors. 
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Figure. 1.3: The crystallography structure of PTP1B. PTP1B has an active site Cysteine 
215 with surrounding catalytic loop (a) and an identified allosteric site (b) which is 
surrounded by the α3 helix, α6 helix and α7 helix. During PTP1B activation, the WPD 
loop (c) moves from the open position to the closed position. Allosteric inhibition aims 
to prevent the WPD loop to keep PTP1B in an inactive state and lose activity. 
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1.2.7 Lupane triterpenes are candidates as PTP1B allosteric inhibitors 
Triterpenes are pentacyclic chemical compounds which are major natural components 
of human diets, isolated from vegetable oils, cereals and fruits (Moreau et al., 2002). 
Previous studies have mentioned the enormous utility of triterpenes as anti-cancer drugs, 
anti-inflammation drugs and anti-diabetes drugs (Ovesna et al., 2004, Liby et al., 2007). 
As one family of triterpenes, lupane triterpenes have been studied for decades. Lupane 
triterpenes are major natural components of vegetables, fruits and medical plants 
including white cabbage, pepper, carrot, pea, birch bark, rosemary leaves and mistletoe 
shoots (Laszczyk, 2009).  Previous studies have established lupane triterpenes as anti-
cancer drugs, anti-inflammation drugs, anti-diabetes drugs and anti-viral drugs (Baltina 
et al., 2003, Tolstikova et al., 2006). Lupane triterpenes have four members including 
lupeol, lupenone, betulin and betulinic acid (Fig.1.4). All four members of lupane 
triterpenes have shown potent PTP1B inhibition activity in vitro (Na et al., 2009, Choi 
et al., 2009, Xu et al., 2009). One previous study has shown that lupeol could inhibit 
PTP1B with a high potency (IC50=5.6M) (Na et al., 2009) and the extra kinetic assay 
indicates that lupeol acts as a non-competitive inhibitor of PTP1B which means lupeol 
is a potential PTP1B allosteric inhibitor. This is because when a compound inhibits the 
enzyme, it could target on either active site as a competitive inhibitor or bind to 
allosteric site as a non-competitive inhibitor. Lupeol fits in non-competitive inhibition 
mode. Therefore lupeol is a potential PTP1B allosteric inhibitor. However, the 
molecular mechanism and the location of the binding site of lupeol and other lupane 
triterpenes targeting PTP1B remains speculative. Considering the promising results for 
the allosteric PTP1B inhibitors, my work aims at characterising the selectivity and 
binding mode of lupane triterpenes targeting PTP1B including lupeol, lupenone, betulin 
and betulinic acid in silico and in vitro, as well as validating their biological and 
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physiological functions in various cellular models, in order to develop ideal potential 
PTP1B allosteric inhibitors in the future. 
 
Figure .1.4: The formula of allosteric ligands used in this study. Compound 2 and 3 
have been reported to be allosteric inhibitors by Wiesmann et al (Wiesmann et al., 2004). 
Four members of lupane triterpenes were selected. It appears that lupeol, lupenone, 
betulin and betulinic acid share a pentacyclic hydrophobic main structure with 
distinctions of functional groups in the R1 and R2 positions.  
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1.2.8 Application of computational modelling to determine lupane triterpenes as 
PTP1B allosteric inhibitors 
The present PhD project applies computational modelling as a method to characterise 
the structural interactions between PTP1B and lupane triterpenes, to demonstrate lupane 
triterpenes as PTP1B allosteric inhibitors. Computer-aided drug discovery plays a 
critical role in the investigation of therapeutically small molecules to develop drug 
candidates (Kubinyi, 2006). As a well-established computational technique, molecular 
docking is applied to predict the preferred orientation of one molecular bond to another 
(Kitchen et al., 2004), such as lupane triterpene to PTP1B. The interactions between two 
molecules are mainly forces including electrostatic forces, van der Waal interactions 
and solvent-related forces. All the types of energy will be detected by a search 
algorithm and then converted into numerical values via a statistical scoring function. 
Docking scores will be provided after the calculation which could help to evaluate the 
most possible binding site of the molecule targeting the protein (Warren et al., 2006). 
The relation between biological molecules always plays an important role in signal 
transduction. By using docking to mimic the interaction between two molecules such as 
lupane triterpene and PTP1B, could provide the information including affinity and 
activity of the lupane triterpenes. However, docking only provides a rigid structure of 
protein-ligand complex which is flexible in nature solvent environment (Kitchen et al., 
2004). Instead, molecular dynamics (MD) simulation is then applied to determine the 
motion of atoms and resulting conformational change of lupane triterpenes upon 
binding to PTP1B. MD calculates a time-dependent trajectory concerning the 
movements of individual particles in a protein-ligand complex, to investigate the 
stability and flexibility of the formed complex, and implicate the important structural 
feature of the ligand and protein binding site involved in forming the bound complex 
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(van Gunsteren et al., 2006). Overall, application of computational modelling aims to 
disclose the binding mode of lupane triterpenes targeting PTP1B allosteric site, and 
reveal the potential drug design strategy to improve efficacy.   
1.2.9 Application of inertial microfluidic platform to separate and collect neurons 
and glial cells 
A cell culture model will be broadly applied in this project including primary neuron 
culture, which is a widely used experimental method, closely mimicking the 
physiological status of neurons in vivo and provides a convincing and convenient 
platform to perform drug treatments. However one major challenge is to separate 
neurons from complex cell mixtures dissected from brain tissues with high purity and 
efficiency. For example, glial cell is the major component in brain tissue which 
normally outnumbers neurons in mammalian brain regions (Bear MF, 2006). Medium-
based procedure is a conventional method for pure neuron and pure glial cell cultures 
where NeuroBasal medium with FDU (5-Fluoro-2′-deoxyuridine) is used to inhibit glial 
cells proliferation (Brewer, 1997, Hilgenberg and Smith, 2007, Medicine, 2015). 
However, such a method requires long-term incubation with chemical treatment, 
wasting both time and experimental materials. Apart from this medium-based separation 
method, immune-specific separation is broadly applied in neuron-related research. 
Fluorescence-activated cell sorting (FACS) and magnetically-activated cell sorting 
(MACS) have been widely used for separating cells (Radbruch and Recktenwald, 1995). 
However, labelling target cells with antibodies may disturb the immunochemistry 
analysis on targets of interest. Therefore, a label-free and high-throughput technique is 
required to continuously separate neurons and glial cells to bridge this gap for 
neuroscience research. On the other hand, there is increasing evidence of glia, in 
particular astrocyte abnormality, modulating synaptic dysfunction in several brain 
` 
20 
 
disorders including schizophrenia (Seifert et al., 2006, Allen, 2014). A recent study 
observed that astrocyte loss in the prefrontal cortex triggered neuronal damage causing 
cognitive impairment in the animal model (Lima et al., 2014). Therefore it is of great 
interest to investigate the specific role of neurons and glia in in vitro schizophrenia-like 
models in future studies. Furthermore, PTP1B has been recently found expressed in 
microglial cells (Song et al., 2016), indicating the need for investigation of glial PTP1B 
contributing to BDNF reduction in the future.  
In the present study, I collaborated with a research group in the department of 
engineering in University of Wollongong, to develop an inertial microfluidic device to 
separate neurons and glial cells. This inertial microfluidic platform has a built-in 
serpentine micro-channel made by Polydimethylsiloxane (PDMS), a bio-compatible 
material, utilizing hydrodynamic forces to continuously separate particles of different 
sizes with high performance (Zhang et al., 2014b) (Fig.1.5). Inertial microfluidics is a 
very promising candidate due to its high throughput and simple structure, it has been 
widely used to extract blood plasma (Lee et al., 2011, Zhang et al., 2014a), isolate 
circulating tumour cells (CTCs) (Mach et al., 2011, Hou et al., 2013, Ozkumur et al., 
2013), and separate leukocytes from blood, (Wu et al., 2012) etc. As a label-free 
technique without the use of antibody affinity, filter or centrifugation, inertial 
microfluidics is highly desirable to ensure minimal damage and alteration to neurons. 
This microfluidic device will be very useful to separate and collect both neurons and 
glia spontaneously from the brain section of interest, and establish a platform to 
characterise the specific role of neuron and glia in neurological disorders. 
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Figure. 1.5: a): The inertial microfluidic device applied in this work. B): Schematic 
illustration of the micro-channel structure used for cell separation. A filter upstream of 
the serpentine channel prevents the channel from being blocked by large debris. A 
trifurcation outlet system was used with middle outlet #1 for neuron collection, two 
symmetrical side branches merged together as outlet #2 for glial cell collection. 
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1.3 Aims 
The aims of this research were to: 
1. Determine lupeol and other lupane triterpenes as PTP1B allosteric inhibitors using 
computational modelling and biological assay, to confirm these compounds specifically 
bind to PTP1B allosteric site and selectively and potently inhibit PTP1B. 
2. Investigate the role of PTP1B regulating BDNF level, BDNF-mediated signalling, 
leptin signalling, synaptogenesis and neurite outgrowth in the PCP-mimicked 
schizophrenia model and Neureglin-1 knockout animal model. 
3. Demonstrate that lupane triterpene treatment is an effective treatment to alter PCP-
induced BDNF reduction and neurogenesis impairment, indicating that PTP1B 
inhibition is a potential therapeutic strategy to be combined with current antipsychotic 
olanzapine to enhance treatment efficacy. 
4.  Develop an innovative microfluidic device to separate neurons and glial cells with 
purity and viability, in order to provide a reliable platform to investigate the specific 
role of neurons and glia in neurological diseases such as schizophrenia and associated 
metabolic disorders. 
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1.4 Hypothesis 
1. Lupeol and other lupane triterpenes are PTP1B allosteric inhibitors which target 
PTP1B allosteric site and form a stable protein-ligand complex. The structure of lupane 
triterpenes will be characterised to provide advice for future chemical modifications. 
Lupane triterpenes are able to specifically inhibit PTP1B over TCPTP, which will be 
examined in this part of study. 
2. PTP1B is significantly altered in Phencyclidine-treated and Neureglin-1 knockout 
model, and thus negatively regulated synaptogenesis and neurite outgrowth through the 
reduction of BDNF, attenuation of BDNF-mediated signalling and impairment of leptin 
signalling. 
3. Lupeol treatment is able to significantly inhibit PTP1B and reverse PCP-induced 
psychopathological alterations to increase BDNF, restore BDNF-mediated signalling 
and leptin signalling, as well as enhance the treatment efficacy and prevent side effects 
of current antipsychotic such as olanzapine. 
4.  An innovative microfluidic device is able to separate neurons and glial cells with 
efficacy and efficiency. Collected neurons and glial cells are healthy and functional to 
perform downstream experiments. 
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1.5 Significance 
1. One challenge in PTP1B inhibition is that most PTP1B inhibitors target the PTP1B 
active site. The PTP1B active site and nearby catalytic domains are highly conservative 
in the PTP family. For example, PTP1B is highly similar to TCPTP in amino acid 
sequence and 3D structure. To inhibit PTP1B with enhanced selectivity, PTP1B 
allosteric site has been discovered as a novel drug target. PTP1B allosteric inhibition is 
able to prevent the conformational change of the WPD loop during catalysis, thus 
keeping PTP1B in an inactivated state. In the present project, I aim to identify lupane 
triterpenes (lupeol, lupenone, betulin and betulinic acid) as novel PTP1B allosteric 
inhibitors.  
2. Reduction of BDNF and attenuation of BDNF-mediated signalling lead to impaired 
neurogenesis which has been recognized in mental disorders including schizophrenia. 
PTP1B has been reported to attenuate BDNF-mediated signalling. PTP1B has also been 
revealed to inhibit leptin signalling which is a crucial factor stimulating BDNF 
expression. Therefore, it is important to investigate the role of PTP1B in the impairment 
of BDNF-mediated signalling and whether PTP1B directly regulates BDNF expression 
through leptin signalling in schizophrenia-mimicked models. 
3. In the present study, lupane triterpene treatment is applied to the PCP treated model 
to reverse PCP-induced alterations including BDNF reduction, BDNF-mediated 
signalling attenuation and synaptogenesis impairment. Furthermore, lupane triterpene 
treatment is applied combined with antipsychotic (olanzapine) treatment to confirm the 
improved efficacy of co-treatment due to PTP1B inhibition. 
4. Neurons are of particular interest in investigating the psychopathology of mental 
illness including schizophrenia. Primary neuron culture is broadly used to collect and 
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analyse neurons in mammalian brain tissue. However, it is difficult to isolate purified 
neurons from cell mixture in brain tissue culture. In the present study, a microfluidic 
device is introduced to separate and collect neurons and glial cells with high purity and 
viability. Moreover, such application will be useful in future studies to differentiate the 
role of neurons and glia in disease development and will be established as drug 
screening platform. 
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1.6 Methods and Materials     
1.6.1 Homology modelling of PTP1B  
In this study, a published PTP1B crystal structure (PDB id: 1T49) was applied. This 
PTP1B structure was an open and inactive conformation which contains 282 amino 
acids, and the 7 (17 amino acids) was not resolved (labelled as PTP1B282). Helix 7 
plays a crucial role in PTP1B allosteric inhibition. However there is no PTP1B crystal 
structure with 7 in the inactive state. Here, homology modelling with Modeller 9v8 
was performed in order to construct the missing helix 7 based on the active 
conformation of PTP1B (PDB id: 1PTY) (labelled as PTP1B299) (Sali and Blundell, 
1993). The best PTP1B299 model based on the DOPE energy was chosen from total 
100 models generated, and then subjected to equilibrium molecular dynamics 
simulations for 40 ns to reach equilibrium and optimize the modelled structure. 
1.6.2 Molecular docking  
Autodock Vina (version 1.1.2) was used to carry out docking studies (Trott and Olson, 
2010). The docking process was established via re-docking previous demonstrated 
PTP1B allosteric inhibitor, compound 2 to PTP1B282 as in the co-crystal structure 
(Wiesmann et al., 2004). The protonation states of the PTP1B titratable groups were 
assigned at pH 7.0 using PROPKA3.1 (Olsson et al., 2011). Docking study was then 
performed sequentially in two steps. Firstly, blind docking was performed in which a 
cube large enough to cover the whole PTP1B protein (75 Å  60 Å  60 Å) was 
established to detect potential binding pockets. Then, focused docking which involved 
localized docking with a smaller cube (22.5 Å  22.5 Å  22.5 Å) was set up, targeting 
the potential binding site of interest (e.g. active site, allosteric site, or other sites of 
interest identified from the previous blind docking procedure). In each focused docking 
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study of lupane triterpenes binding to PTP1B282 and PTP1B299, total 20 
conformations of the PTP1B-ligand complexes which showed lowest binding affinities 
were listed for further analysis. The best binding mode from docking study was selected 
as the initial structure for the following molecular dynamics simulations. Multiple 
dockings based on different snapshots collected from equilibrium molecular dynamics 
simulations (PTP1B282 and PTP1B299), were also performed. Qualitatively, the 
identified populated binding poses are similar. In addition, blind docking of lupane 
triterpenes targeting TCPTP (1L8K) was performed. 
1.6.3 Molecular dynamics simulations  
Molecular dynamics simulations were established to characterise the stability and 
flexibility of the PTP1B-lupane triterpenes complexes. In this study, total 9 different 
systems were set up (PTP1B282, PTP1B282 with Compound2, PTP1B282 with Lupeol, 
PTP1B299, PTP1B299 with Compound2, PTP1B299 with Lupeol, PTP1B299 with 
Lupenone, PTP1B299 with Betulin, PTP1B299 with Betulinic acid). All of the systems 
were solvated in a box full of TIP3P water molecules, which extended about 12 Å from 
the surface of the protein. Then counter ions of Na
+ 
were applied to neutralize the 
systems. The salt (NaCl) concentration was set to 0.15 mol/L. Molecular dynamics 
simulations were carried out using NAMD 2.9 (Phillips et al., 2005). The protein and 
the ligands were represented with the GAFF force field (Wang et al., 2004) and the non-
polarizable CHARMM PARAM27 force field (MacKerell et al., 1998), respectively. 
Langevin algorithm was applied to set up periodic boundary conditions for all of the 
systems, maintaining the temperature at 298.15 K, and the Langevin Piston Nose-
Hoover method was used to keep the pressure constant at 1.0 bar. Particle Mesh Ewald 
(PME) method (Darden et al., 1993) was performed to calculate the electrostatic 
interactions. The van der Waal forces were treated with a cut-off at 12 Å. All of the 
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covalent bonds which involved hydrogen were kept rigid applying the Rattle algorithm 
and the time step was set to 1.0 fs. In the equilibrium simulations of PTP1B homology 
modelling, a harmonic restraint on the backbone atoms except 7 was established with 
a decreasing force constant from 64.0 to 1.0 kcal/mol/Å
2 
for 10 ns. The simulations 
continued for 30 ns without any restraints. For the molecular dynamics simulations of 
the docked complexes, a harmonic restraint on the backbone atoms was setup with a 
decreasing force constant from 32.0 to 1.0 kcal/mol/Å
2 
for 3 ns followed by 20 or 100 
ns equilibrium simulations. 
1.6.4 Binding free energy calculation  
Free energy perturbation distributed replica-exchange molecular dynamics (FEP/-
REMD) (Woods et al., 2003, Jiang et al., 2009) was carried out to calculate binding free 
energy of lupeol and betulinic acid binding to PTP1B. The reason to perform 
computationally intensive absolute binding free energies is because the binding modes 
for lupeol and betulinic acid revealed by docking and subsequently molecular dynamics 
simulations are rather different. Therefore it is difficult to apply relative binding free 
energy calculations, which assume that the available conformational spaces are strongly 
overlapped (Hansen and van Gunsteren, 2014). Based on previous literature, free energy 
difference was called between the unbound ligand in the aqueous solution and the 
bound ligand in the binding site of the target protein as the absolute binding free 
energies. The total free energy was divided into four terms, namely repulsive and 
dispersive components of the Lennard-Jones potential based on the Weeks-Chandler-
Anderson scheme, the electrostatic contribution, and the restraining potential. Ligand 
was decoupled from the environment in four steps through four thermodynamic 
coupling parameters (). No corrections have been carried out to the potential 
electrostatic finite-size artefacts (Rocklin et al., 2013, Reif and Oostenbrink, 2014). In 
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order to accelerate the convergence, each -staging FEP window was treated as a 
replica and the -exchange occurred along the entire alchemical reaction path. This 
method has been successfully applied to study which investigated the interactions 
between glycoside hydrolases and polysaccharides (Payne et al., 2013). For both 
PTP1B-lupeol and the PTP1B-betulinic acid complex in this study, FEP/-REMD 
simulations started from a 100 ns equilibrated snapshot. Total set of 64 replicas 
including 36 repulsive, 12 dispersive, and 16 electrostatic, was carried out in the 
simulations with an exchange frequency of one every 1,000 steps (1 ps). In each replica, 
1.0 ns simulations were performed in which the last 0.8 ns simulations were averaged to 
calculate the ligand binding free energies. The protein-ligand complexes contained a 
positional translational restraint with a force constant of 10.0 kcal/mol/Å
2
. The error 
analyses were assigned using four sequential simulations of 0.2 ns each.  
1.6.5 Trajectory analysis  
Trajectory snapshots were saved every picosecond (i.e. every 1,000 steps). Either the 
molecular visualization program VMD 1.9 (Humphrey et al., 1996) or CHARMM 
(Brooks et al., 2009) was performed to analyse the trajectory data.  
1.6.6 PTP1B and TCPTP inhibition assay of lupane triterpenes by pNPP 
phosphatase assay  
EnzoLyte Colorimetric pNPP Protein Phosphatase Assay kit (AS-71105, Anaspec) was 
applied to determine the inhibitory effects of lupane triterpenes targeting PTP1B and 
TCPTP. The recombinant human PTP1B (ab42572, Abcam Inc), recombinant human 
TCPTP (ab42575, Abcam Inc), Lupeol (L5632, Sigma-Aldrich), lupenone (1617-70-5, 
Faces Biochemical Co.Ltd), betulin (B9757, Sigma-Aldrich), betulinic acid (B8936, 
Sigma-Aldrich) and compound 3 (765317-72-4, Merck Millipore) were dissolved in 
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Dimethyl sulfoxide (DMSO) or water. Experiment was processed based on 
manufacturer instructions. Briefly, 25 ng PTP1B or TCPTP was incubated in different 
concentrations of compounds (control drug compound 3, lupeol, lupenone, betulin, 
betulinic acid) for 10 min in assay buffer (assay kit supplied) at 25C, and then the 
reaction was initiated by adding the 20 mM pNPP reagent and stopped by NaOH (assay 
kit supplied)  after 30 min at 25C. All readings were detected and recorded using a 
spectraMAX 384 microplate spectrophotometer. The absorbance was set up at 405 nm. 
Negative control wells without enzymes were calibrated. The PTP1B and TCPTP 
inhibition potency of the lupane triterpenes was determined by IC50, calculated using the 
GraphPad Prism 5 program (GraphPad Software Inc).  
1.6.7 PTP1B inhibition kinetics assay of lupane triterpenes by pNPP phosphatase 
assay  
The kinetics assay of PTP1B-catalysed hydrolyses in the presence of betulin and 
betulinic acid were performed using the pNPP Protein Phosphatase Assay kit described 
above. The reaction mixture consisted of six different concentrations of pNPP (1.0, 2.0, 
4.0, 8.0, 16.0, and 20.0 mM) as PTP1B substrate and different concentrations of lupeol, 
betulin, and betulinic acid. The Lupeol group was set up as a control group. The 
absorbance at 405 nm was detected by a spectraMAX 384 microplate 
spectrophotometer twice every minute for a total of 15 min. Michaelis-Menten constant 
(Km) and maximum velocity (Vmax) of PTP1B were determined via Lineweaver-Burk 
plots using the GraphPad Prism 5 program (GraphPad Software Inc). 
1.6.8 Immunoprecipitation assay of PTP1B 
Based on the instructions of the Pierce Classic IP Kit (26146, Thermo Fisher Scientific 
Inc) with minor modifications (Lorenz, 2011), PTP1B was detected using the 25 𝜇g 
` 
31 
 
PTP1B antibody (sc-1718, Santa-Cruz) for 12 h at 4℃ to form immune complexes. 
Immune complexes were then isolated by adding the protein G-agarose, washed three 
times in the phosphatase assay buffer from the EnzoLyte Colorimetric pNPP Protein 
Phosphatase Assay kit (AS-71105, Anaspec), and resuspended in the same buffer. 
Samples were analysed for the phosphatase activity using the same pNPP assay kit 
mentioned above. 
1.6.9 Ethics statement 
This study was approved by the Animal Ethics Committee, University of Wollongong 
(Application Approval #: AE15/13 and AE16/01), and complied with the ‘Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes’ (Australian 
Government National Health and Medical Research Council, 2004), in accordance with 
the International Guiding Principles for Biomedical Research Involving Animals. All 
efforts have been performed to minimize animal numbers, animal stress and prevent 
suffering. 
1.6.10 Primary cell culture of wide type and Nrg1 -/+ mouse hypothalamic neurons  
In chapter 3 and chapter 4, primary hypothalamic cell cultures from hypothalamic 
tissues of postnatal day 0 (PN0) wild-type (WT) and Neuregulin-1 (NRG1)-knockout 
(KO) C57BL/6 mice were prepared based on previous literature (Hilgenberg and Smith, 
2007). The culture medium was adapted according to Johns Hopkins online protocol 
(Medicine, 2015), which was composed of 480 ml NeuroBasal medium (21103-049, 
Gbico) with additive 10 ml B27 (17504-044, Gbico), 5ml glutamine (25030081, 
Thermo Fisher Scientific Inc), 5 ml penicillin-streptomycin (15140122, Gbico) and 9 g 
glucose (G7021, Sigma-Aldrich). Neurons were plated at either a final density of 1.5 × 
10
5
 cells per cm
2
 onto Poly-D-Lysine-coated coverslips for immunofluorescence 
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imaging (G400-13, ProSciTech) or a final density of 5 × 10
5
 cells per cm
2
 into Poly-D-
Lysine-coated 12-well cell culture plate for collect protein or RNA, and maintained at 
37°C with 5% CO2. At DIV 10, 25 µM PCP (P3209, Sigma-Aldrich) was applied to 
neurons for 3h and 48h. To investigate effect of PCP on leptin signalling, 100 nM leptin 
(450-31-5000, PeproTech) was applied to neurons after PCP stimulations for 4 hours. 
To examine the influence of PTP1B inhibition on neurite synaptogenesis, 50 µM lupeol 
(L5632, Sigma-Aldrich) was administrated to primary hypothalamic neurons which 
have been treated by 25 µM PCP for 24 hrs, and then co-incubated for another 24 hrs. 
The DMSO concentration was controlled below 0.5%. Neurons were then collected for 
further experiments including immunofluorescence imaging, qRT-PCR and western blot. 
1.6.11 Mouse hypothalamic cell line culture 
The mouse hypothalamic A-59 neurons (mHypoA-49 neurons, CELLutions) and mouse 
hypothalamic E-46 neurons (mHypoE-46 neurons, CELLutions) were grown in 
monolayer in Dulbecco’s modified Eagle medium (DMEM) (D5796, Sigma-Aldrich) 
with 10% foetal bovine serum (FBS) (SFBS-F, Bovogen Biologic.Pty.Ltd) and 1% 
penicillin/streptomycin. Hypothalamic cells were maintained at 37C with 5% CO2. In 
Chapter 2, to detect PTP1B inhibition of lupeol and betulinic acid, Murine TNFα 
(T7539, Sigma-Aldrich) was applied to induce PTP1B expression in cell, Lupeol and 
betulinic acid were dissolved in Dimethyl sulfoxide (DMSO), then diluted in sterile 
water, and mixed with serum free cell culture medium. The DMSO concentration was 
controlled below 0.5%. The final concentrations of lupeol and betulinic acid in the cell 
culture medium were 28 µM (5 of the IC50 value) and 7.5 µM (5 of the IC50 value), 
respectively. In chapter 3, to expose the role of PCP in hypothalamic cell line, 
administration of 1 µM PCP (low dosage) or 25 µM PCP (high dosage) (P3209, Sigma-
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Aldrich) were applied to neurons for 3 and 48 hrs. To investigate the NMDA receptor 
subunit involved in PTP1B expression, both low dosage (5 µM) and high dosage (50 
µM) of NR2A antagonist Peaqx (I2892, Sigma-Aldrich) and NR2B antagonist 
ifenprodil (P1999, Sigma-Aldrich) were administrated to cell line for 24 and 48 hrs. To 
reveal the signalling pathway involved in PCP induced leptin signalling dysfunction, 
100 nM leptin (450-31-5000, PeproTech) was administrated to cells for 4 hrs after PCP 
3 and 48 hrs. Prior to leptin treatment, the cell culture medium was replaced with serum 
free medium for 4 hrs. To investigate the effect of PTP1B inhibition in hypothalamic 
cells, 10 µM and 50 µM PTP1B inhibitor Lupeol and 5 µM atypical antipsychotic 
Olanzapine (O1141, Sigma-Aldrich) were dissolved in Dimethyl sulfoxide (DMSO), 
then diluted in sterile water, and mixed with serum free cell culture medium. Cells were 
exposed to 25 µM PCP for 48 hours and replaced with serum free cell culture medium, 
then lupeol treatment, olanzapine treatment and co-treatment were applied to cells for 
24 hrs individually. The DMSO concentration was controlled below 0.5%.  
1.6.12 Immunofluorescence and image analysis 
For immunochemical staining, primary neurons and primary glial cells were washed by 
PBS and fixed with 4% paraformaldehyde in Dulbecco's PBS for 30 min at room 
temperature. The samples were further incubated with 100% methanol for 10 min in -
20°C, and blocked with 5% donkey serum in phosphate buffered saline teween20 
(PBST) for 1 hr at 37 °C. Then, anti-PTP1B antibody (SAB1306060, Sigma-Aldrich), 
anti-BDNF antibody (SC-20981, Santa-Cruz), anti-SYN antibody (701503, Life 
Technnology), anti-microtubule-associated protein 2 (MAP2) antibody (M9942, Sigma-
Aldrich), anti-NeuN antibody (MAB377, Merck Millipore) and anti-Glial Fibrillary 
Acidic Protein (GFAP) antibody (G9269, Sigma-Aldrich) were applied overnight at 4°C. 
PTP1B, SYN, BDNF and GFAP were visualized with isotype-specific donkey anti-
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rabbit IgG (H+L) secondary antibody conjugated with Alexa Fluor 488. MAP2 and 
NeuN were visualized by donkey anti-mouse IgG (H+L) secondary antibody conjugated 
to Alexa Fluor 594. The concentrations of antibodies were applied following 
manufacturer manuals. A confocal microscope (Leica TCS SP5 Advanced System, 
Leica Microsystem) was used to obtain images. Software Image J. 10 
(http://rsbweb.nih.gov/ij/download.html) with plugin NeuriteQuant (Dehmelt et al., 
2011) was applied to quantify the immunoreactivity based on from 5 independent 
culture wells.     
1.6.13 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed as previously described (Yu et 
al., 2013b). Neurons were collected for RNA extraction via Aurum
TM
 Total RNA Mini 
Kit (7326820, Bio-Rad Laboratories) and reversed to cDNA by using Applied 
Biosystems
TM
 High Capacity cDNA Reverse Transcription Kit (4368814, Life 
Technology). Real-time PCR was then performed via SensiFAST
TM
 SYBR No-ROX 
Kit (BIO-98005, Bioline).  The mRNA expression levels of PTP1B (Forward: 
TGGCCTGACTTTGGAGTCCC; Reverse:  CTCCAGTGTGCGTTTGGGTG.), SYN 
(Forward: GAACAAGTACCGAGAGAACAACAA; Reverse: 
GGTCAGTGGCCATCTTCACA.), BDNF (Forward: 
GGGTCACAGCGGCAGATAAA; Reverse: GCCTTTGGATACCGGGACTT.) and 
TCPTP (Forward: AGAGTGGCCAAGTTTCCAG; Reverse: 
CACACCATGAGCCAGAAATG.) were normalized to γ-actin (Forward: 
GCTAACAGAGAGAAGATGACG; Reverse: CAGATGCATACAAGGACAGC), 
which served as the internal control. Experiments were performed in triplicate. 
1.6.14 Western blot analysis  
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Detailed protocols were described in our previous study (Yu et al., 2013b), primary 
cultured hypothalamic neurons, mHypoA-59 cells and mHypoE-46 cells were washed 
with ice-cold phosphate buffered saline (PBS) and lysed in NP-40 lysis buffer 
(FNN0021, Invitrogen) containing a protease inhibitor cocktail, beta-glycerophosphate 
(Sigma-Aldrich) and phenylmethanesulfonyl fluoride (PMSF) (Sigma-Aldrich). Cell 
lysates were centrifuged at 14,000 rpm for 10 min at 4C. The supernatants were 
collected and protein concentrations were determined using the DC
TM
 Protein Assay kit 
(5000121, Bio-Rad Laboratories) was used according to the manufacturer instructions. 
Equal amounts of protein (15 𝜇g) were separated on 4-20% CriterionTM TGX TM Precast 
Gels (567-1095, Bio-Rad Laboratories) using SDS-PAGE. Following electrophoresis 
(120 V for 1.5 h), the proteins were transferred to polyvinylidene difluoride membranes 
(100 V for 1 hr). Membranes were blocked in 5% bovine serum albumin (BSA) or 5% 
skim milk depending on the primary antibodies used, followed by incubation with the 
primary antibodies anti-PTP1B (SAB1306060, Sigma-Aldrich), anti-BDNF antibody 
(SC-20981, Santa-Cruz), pNR2B
Tyr1472
 (4208S, Cell Signaling Technology), NR2B 
(4207S, Cell Signaling Technology), anti-pAkt
Ser473 
(D9E, Cell Signaling Technology), 
anti-Akt (SC8312, Cell Signaling Technology), anti-pGSK3β
Ser9
 (5B3, Cell Signaling 
Technology), GSK3β (D75D3, Cell Signaling Technology), pJAK2
Tyr1007/1008
 (C80C3, 
Cell Signaling Technology), JAK2 (D2E12, Cell Signaling Technology), pSTAT3
Tyr705
 
(D3A7, Cell Signaling Technology), STAT3 (79D7, Cell Signaling Technology) and 
anti-actin (MAB1501, Merck Millipore) in 1% BSA or 1% skim milk overnight at 4C. 
Following washes (3 x 5 min) in Tris Buffered Saline + 0.1% Tween 20, membranes 
were incubated with respective secondary antibodies for 1 hr at 25C. Blots were 
visualized using Amersham
TM
 ECL
TM
 Detection Reagents (RPN2106, Ge Healthcare) 
and exposed in dark room. The bands corresponding to the proteins of interest were 
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scanned and analysed using the automatic imaging analysis system Quantity One (Bio-
Rad Laboratories). All quantitative analyses were normalized to actin.  
1.6.15 Neuron Neuropeptide Y (NPY) detection  
The mouse hypothalamic NPY/GFP neurons (mHypoA-NPY/GFP neurons, 
CELLutions) were cultured in the 96-well plate in the same incubation condition as 
mHypoA-59 neurons. 5µM olanzapine, 50µM lupeol and co-treatment of olanzapine 
and lupeol were applied to neurons. After 6h treatment, discard culture medium and 
measure neuron NPY-bound GFP immunoactivity using FlexStation 3 (Molecular 
Devices). Wavelength of detection is set from 488 nm to 510 nm, cut-off at 495 nm.   
1.6.16 Design and fabrication of inertial microfluidic device 
The serpentine channel used in our experiments consists of 15 zigzag periods; the 
channel has a uniform 42 µm depth, and the length and width of each U-turn are 700 
µm. The micro-channel is 200 µm wide. A trifurcating outlet at the end of the channel is 
implemented at the end of the serpentine channel. Two-sided symmetrical bifurcations 
are combined into a single outlet to simplify the collection of two-sided streams. The 
microfluidic device was fabricated by the standard photolithography and soft 
lithography techniques (Duffy et al., 1998) (provided by collaborator). Prior to these 
cell experiments, the device was rinsed with phosphate buffered saline (PBS) at 100 
µl/min for 10 min using a syringe pump (Legato 100, Kd Scientific), after which the 
devices were sterilized through exposure to UV light for 30 min. 
1.6.17 Inertial microfluidic separation of neurons and glia 
Primary neurons and glia were prepared based on 1.6.10, Hypothalamic tissues were 
digested and triturated to suspend cells in 7 ml culture medium. 2 ml cell suspension 
was assigned as an Inlet group for comparison, while the other 5 ml suspension of 
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hypothalamic cell mixture was infused into the inertial microchip to perform separations 
under different flow rates (350 µl/min, 550 µl/min, 750 µl/min). Separated cells were 
collected from the Outlet Middle and Outlet Aside under three typical flow rates 
respectively. Separation efficacy was applied to determine the optimal flow rate. Cells 
separated from optimal flow rate were collected for further culture and tests. Purity of 
separation and enrichment ratio were measured to evaluate separation performance. 
Separation purity is defined as the ratio of target cells number to the total cells number, 
while enrichment is determined as the ratio of target cells concentration from the outlet 
to the target cells concentration from the inlet. 
1.6.18 Statistical analysis 
Data in the present study were analysed using the SPSS 19 statistical package (SPSS, 
Chicago, IL). T-test and One-way analysis of variance (ANOVA) followed by the post-
hoc Tukey-Kramer honestly significant difference (HSD) test were carried out based on 
individual experiments. Data were expressed as mean ± SEM, and P < 0.05 was 
considered statistically significant. 
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1.7 Summary 
Current challenge in PTP1B drug discovery was mentioned that PTP1B traditional 
inhibitors hardly inhibit PTP1B with potency, selectivity and lack of bioavailability. 
PTP1B traditional inhibitors target PTP1B active site, which is highly similar to other 
members of PTPs in both amino acid sequence and 3D structure. Therefore PTP1B 
allosteric inhibition was introduced which targets PTP1B unique allosteric site, making 
PTP1B allosteric inhibition as a promising strategy for drug discovery. Here I proposed 
lupane triterpenes as PTP1B allosteric inhibitors candidates based on the properties 
shown in previous literatures. Computational modelling combined with biological 
assays and cell culture will be applied to confirm lupane triterpenes as PTP1B allosteric 
inhibitors.  
Furthermore, I reviewed the rising evidences which reported that PTP1B impaired 
neurite outgrowth and synaptogenesis via attenuating BDNF-mediated signalling. All 
these evidences indicated that PTP1B may have a crucial role modulating impaired 
neurogenesis in neurological disorders such as schizophrenia and PTP1B inhibition 
could be an alternative medication treatment. Phencyclidine (PCP)-treated model and 
neuregulin-1 knock-out model were introduced which have been broadly applied to 
mimic psychopathology of schizophrenia and testify treatment effects. Both models will 
be applied to investigate the role of PTP1B contributing to BDNF reduction and 
attenuation of BDNF-mediated signalling. Moreover, lupane triterpene will be applied 
to determine that PTP1B inhibition is a potential therapeutic strategy.  
At last, the current issue in primary cell culture was discussed which is the difficulty to 
collect purified and enriched neurons and glia  without chemical reagent and antibody 
disturbance. In the present study, inertial microfluidic microchip will be introduced to 
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spontaneously separate and collect both neurons and glia. Importantly, interest in glial 
cell is rising due to increasing evidences revealed the glia dysfunction in several brain 
disorders including schizophrenia with significant cognitive impairments. 
Consequently, an effective and efficient platform is required to separate and collect 
neurons and glia from the same brain section of interest at the same time to establish co-
culture system in the future study, Microfluidic-based technology will meet this 
requirement and broadly applied in the future study. 
In conclusion, the present study will firstly apply computational modelling and 
biological assays to determine lupane triterpenes as novel PTP1B allosteric inhibitors in 
chapter 2. Then schizophrenia-mimicked models will be used to investigate the role of 
PTP1B in BDNF reduction and neurogenesis impairment, and determine PTP1B 
allosteric inhibition by lupane triterpenes is a potential therapeutic strategy in chapter 3. 
Inertial microfluidic separation to collect purified and functional neurons and glia will 
be performed and discussed in chapter 4. 
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Chapter Two 
 
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein 
tyrosine phosphatase 1B 
Reprinted from Scientific Report, Open-access 
 
Available at: http://www.nature.com/articles/srep20766 
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Chapter Three 
Protein Tyrosine Phosphatase 1B mediates phencyclidine-induced BDNF reduction and 
neurogenesis impairment in hypothalamic neurons 
Submitted to Scientific Report on 2016.7 
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Abstract: 
Protein Tyrosine Phosphatase 1B (PTP1B) inhibits BDNF-mediated signalling and 
attenuates leptin signalling, which can impair neurite outgrowth and synaptogenesis. On 
antagonizing the N-methyl-D-aspartate receptor (NMDAR), we found that the 
psychotomimetic drug phencyclidine (PCP) reduces neurite outgrowth and 
synaptogenesis with a significantly increased PTP1B in the hypothalamic neurons. We 
further characterised that it is NR2B, but not NR2A antagonist responsible for the 
increased PTP1B. Moreover, PTP1B was increased in the hypothalamic neurons of 
neuregulin-1 knock out mice in which the decreased hypothalamic NR2B 
phosphorylation was confirmed. PCP decreased neurite outgrowth and synaptogenesis 
via an increased PTP1B and decreased BDNF level, BDNF-mediated-Akt/GSK3β, and 
synaptophysin. Furthermore, leptin increases BDNF expression and promotes 
synaptogenesis which is also impaired by PCP-induced PTP1B. PTP1B directly 
inhibited JAK phosphorylation and thus attenuated leptin signalling and pSTAT3, 
leading to reduced BDNF. Therefore, we proposed that PTP1B-JAK2-STAT3 pathway 
contributed to PCP-induced BDNF reduction. Importantly, we showed that lupeol, a 
specific PTP1B allosteric inhibitor, significantly reduced PTP1B expression and 
improved antipsychotic drug’s effect on BDNF, leptin signalling, neurite outgrowth and 
synaptogenesis, as well as prevent antipsychotic drug induced orexigenic 
neurotransmitter, neuropeptide Y (NPY) production.  
 
Key words: PTP1B; phencyclidine; BDNF; leptin; PTP1B allosteric inhibitor 
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Significance Statement: This study determined hypothalamic PTP1B as a new 
contributor to BDNF reduction and neurogenesis impairment in phencyclidine (PCP)-
mimicked schizophrenia model. BDNF reduction was broadly observed in 
schizophrenia patients and PCP models however the mechanism remains unclear. Here 
we characterised that PCP-induced PTP1B directly inhibited pJAK2 which blocked 
leptin signalling and downstream pSTAT3, resulting in reduction of BDNF protein and 
mRNA level, further attenuated BDNF-mediated Akt/GSK3β and synaptogenesis in 
PCP-treated model. Therefore we proposed PTP1B as a new drug target to reverse PCP-
induced alterations. PTP1B allosteric inhibitor was applied which significantly restored 
BDNF and improved antipsychotic drug, olanzapine’s treatment effect. PTP1B is an 
obesity related protein. Here PTP1B inhibition prevented olanzapine-induced 
neuropeptide Y production which caused obesity as side effects in clinical. 
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Introduction: 
Protein Tyrosine Phosphatase 1B (PTP1B) is highly expressed in the brain tissue. 
Studies have shown that PTP1B influences neurite outgrowth, synaptogenesis and 
cognition. For example, the reduction of hippocampal PTP1B expression improves 
dendritic filopodia, learning and memory (Fuentes et al., 2012). An overexpression of 
PTP1B decreases brain derived neurotrophic factor (BDNF) and its receptor TrkB 
signalling; however, inhibition of PTP1B restores BDNF-mediated neurite outgrowth 
and synaptogenesis (Ozek et al., 2014). Krishnan etc. further demonstrated PTP1B as a 
negative regulator of tyrosine phosphorylation of TrkB to inhibit BDNF signalling in 
neurological disorder in Rett syndrome model (Krishnan et al., 2015). PTP1B is 
expressed in the hypothalamus, in which a neuropathology of schizophrenia has been 
indicated (Fannon et al., 2000, Zabolotny et al., 2002, Walker et al., 2008, Bernstein et 
al., 2010). Decreased BDNF expression is found in a number of mental disorders 
including schizophrenia (Angelucci et al., 2005, Favalli et al., 2012). Therefore it is of 
great interest to investigate the role of hypothalamic PTP1B in modulating BDNF-
mediated neurite outgrowth and synaptogenesis in schizophrenia relevant cell models.   
Previous study shows that PTP1B attenuates leptin signalling (Zabolotny et al., 2002). 
The adipocyte-secreted hormone leptin promotes synaptogenesis and maintains neural 
dendritic morphology as well as regulates energy homeostasis and facilitates learning 
and memory (Bariohay et al., 2005, Komori et al., 2006, Yamada et al., 2011). Leptin 
increases neurite outgrowth and synaptogenesis in mouse H19-7 HN neural cell lines, as 
well as stimulates hippocampal neurogenesis by increasing cell proliferation and 
differentiation (Moon et al., 2013), while memory deficits or decreased synapse density 
has been reported in leptin or leptin receptor deficient rodents such as ob/ob mice, db/db 
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mice and fa/fa rats (Li et al., 2002, Bouret et al., 2004, Pinto et al., 2004, Farr et al., 
2006). Leptin stimulates BDNF expression in the dendrites of hypothalamic neurons 
(Liao et al., 2012). Leptin signalling is activated by Janus Kinase 2 (JAK2) 
phosphorylation and leads to downstream signal transducer and activator of 
transcription 3 (STAT3) expression (Bjorbaek and Kahn, 2004), which has been 
confirmed to benefit neurite outgrowth (Miao et al., 2006, Ng et al., 2006). 
Phencyclidine (PCP), a non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist, can induce schizophrenia-like behaviors in humans and rodents (Morris et 
al., 2005). It is known that PCP decreases neurite outgrowth and dendritic spine density 
both in vitro and in vivo (Hajszan et al., 2006, Adachi et al., 2013). However, the exact 
mechanism is still unclear. It is known that PCP decreases BDNF expression and its 
downstream Akt and GSK3β expression (Adachi et al., 2013). Recently, PTP1B has 
been revealed to inhibit BDNF signalling (Ozek et al., 2014, Krishnan et al., 2015). We 
hypothesize that PTP1B may be involved in PCP induced reduction of BDNF and 
impaired Akt and GSK3β signalling pathway. Furthermore, leptin has been revealed to 
stimulate NMDA-induced intracellular Ca
2+
 levels and facilitates NMDA in modulating 
synaptic plasticity (Shanley et al., 2001). Therefore it will be interesting to investigate 
whether PTP1B is involved in linking NMDA hypofunction and leptin signalling in 
PCP-mimicked schizophrenia modelling. 
In this study, PCP was administrated to primary hypothalamic neurons and 
hypothalamic cell line to examine if hypofunction of NMDA receptor enhance PTP1B 
expression, followed by investigation of NMDA receptor subunit 2A (NR2A) or 
NMDA receptor subunit 2B (NR2B) specific effect using their antagonists. 
Furthermore, PCP’s effects on BNDF and its downstream signalling, synaptogenesis 
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and leptin signalling were examined. To investigate if these specific effects induced by 
PCP were via PTP1B, Lupeol, PTP1B allosteric inhibitor, was pretreated to prevent 
PCP’s effects. Furthermore, co-treatment of lupeol and antipsychotics, olanzapine were 
applied to investigate if hypothalamic PTP1B as a potential target to improve mental 
disease treatment such as schizophrenia. 
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Results: 
PTP1B expression responds to PCP stimulation 
In a hypothalamic cell line, we observed the dose and time response effects of PTP1B 
expression following PCP administration. After 3 hours treatment, PCP significantly 
increased PTP1B (+50%) expression at dose 25µM but not 1µM (Fig.1a). After 48 
hours treatment, PCP increased PTP1B in both 25µM (+60%) and 1µM (+30%) doses 
(Fig.1b). PCP increases PTP1B in dose and time dependent manner. In primary culture 
(DIV 10) of hypothalamic neurons, we treated the neurons with 25µM PCP for 3 and 48 
hours. PTP1B immunoreactivity level was observed with 1.5-fold increase compared to 
control after 48-h treatment by quantification of MAP2-positive living cells (Fig.1c and 
1d). To confirm our findings, we used RT-PCR to examine the PTP1B mRNA level. 
We observed similar results as there was a 2.2-fold increase in PTP1B mRNA level 
after 48 hours of 25µM PCP treatment (Fig.1e). 
NR2B antagonist, but not NR2A antagonist, increases PTP1B expression in the 
hypothalamic neurons 
PCP is a non-competitive NMDA receptor antagonist (Paoletti and Neyton, 2007). 
NMDA receptor consists of NR1 and NR2 subunits. NR2A and NR2B are primarily 
responsible for PCP induced behaviour changes in experimental animals (Anastasio et 
al., 2009, du Bois et al., 2012). To investigate the role of NR2A and NR2B on PTP1B 
regulation, specific NR2A antagonist Peaqx and NR2B antagonist ifenprodil were used 
to examine the changes of PTP1B expression in the hypothalamic cells. Both low 
dosage (5µM) and high dosage (50µM) of each two antagonists were tested for 24 and 
48 hours. After 24 hours exposure, high dose of ifenprodil enhanced PTP1B protein 
level (1.5-fold compared to control), while low dose did not significantly increased 
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PTP1B (Fig.2a). When the incubation of ifenprodil was extended to 48 hours, low 
dosage group showed 1.5-fold increased PTP1B expression compared to control 
(Fig.2b). Similar to PCP, NR2B antagonism increases PTP1B expression in both dose 
and time dependent manner. However, NR2A antagonist Peaqx showed no change on 
PTP1B expression at neither low nor high doses or on 24 and 48 hour stimulation 
(Fig.2c and 2d). We suggest that NR2B antagonism is responsible for increased PTP1B 
expression in hypothalamic cells. We further confirmed that PCP and ifenprodil 
treatments reduced NR2B phosphorylation (Fig.S3). 
Neuregulin-1 (Nrg1) gene knockout leads to a decreased pNR2B, but an increased 
PTP1B 
Previous study showed that NR2B phosphorylation requires normal Nrg1 signalling in 
the prefrontal cortical neurons (Zhang et al., 2016). We found that Nrg1 knockout mice 
had a significantly decreased NR2B phosphorylation in the primary hypothalamic 
neurons (Fig.2e), which is similar to a decreased NR2B phosphorylation and NMDA 
receptor hypofunction reported in hippocampal neurons (Bjarnadottir et al., 2007). This 
suggests that Nrg1 gene mutation could lead to NR2B hypofunction. Furthermore, we 
found a significantly increased PTP1B immunoreactivity level by 1.7-fold in the 
hypothalamic neurons of Nrg1 knockout mice compared to wild type mice (Fig.2f and 
2g). Furthermore, we showed that 25µM PCP did neither increase PTP1B 
immunoreactivity level nor decrease NR2B phosphorylation in Nrg1 knockout mice 
(Fig.2f and 2g).  
PCP attenuates leptin JAK2/STAT3 pathway and leptin-mediated BDNF level  
PTP1B has been reported to dephosphorylate JAK2, a kinase to activate leptin 
signalling STAT3 (Ahima and Flier, 2000, Zabolotny et al., 2002). We have shown in 
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above that PCP increased PTP1B. In this part of study, we examined leptin signalling 
pathway molecules. We used 25µM PCP to treat the hypothalamic cells for 3 hours and 
48 hours, followed by100nM leptin treatment for 4 hours. Leptin alone significantly 
increased 1.4-fold JAK2 phosphorylation and 1.5-fold STAT3 phosphorylation (Fig.3a) 
which was not case in PCP co-treatment groups in neither 3 hours nor 48 hours (Fig.3a), 
suggesting that PCP impairs leptin signalling. We further showed that leptin increased 
BDNF immunoreactivity level by 45% compared to vehicle group similar to what has 
been reported previously (Komori et al., 2006); however, PCP co-treatment group 
showed that leptin was no longer able to increase BDNF (Fig.3b and 3c). To confirm 
these data, we also measured BDNF mRNA level after leptin treatment or leptin and 
PCP co-treatment for 3 and 48 hours, which showed similar findings (Fig.3d). 
Therefore, we showed that PCP increased PTP1B and blunted leptin-induced increases 
of JAK2, STAT3 and BDNF expression, which could contribute to the reduction of 
neurite outgrowth and synaptogenesis induced by PCP.  
PCP reduces hypothalamic neuronal BDNF expression 
After 3-h treatment, PCP (25µM) significantly (-40%) decreased BDNF expression in 
hypothalamic cells, but not at low dose (1µM) (Fig.4a). On the other hand, both low and 
high PCP doses reduced BDNF expression after 48 hour treatment (Fig.4b), indicating 
that PCP suppressed BDNF protein level in a dose- and time-dependent manner in the 
hypothalamic cells. Furthermore, primary culture of hypothalamic neurons (at DIV 10) 
were exposed to 25µM PCP for 48 hours showing 70% reduction of BDNF 
immunoreactivity level compared to control group (Fig.4c and 4d) and 50% inhibition 
of BDNF mRNA level (Fig.4e). Therefore, we have shown that 25µM PCP treatment 
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for 48 hours had strongest effect in BDNF expression in both hypothalamic cell line and 
primary cultured neurons.  
PCP reduces hypothalamic neuronal Akt/GSK3β signalling and synaptic protein  
It is known that BDNF increases the levels of the synaptic vesicle proteins 
synaptophysin (Tartaglia et al., 2001), in which Akt/GSK3β signalling pathway has 
been largely involved (Smillie et al., 2013). Since we have found that PCP increased 
PTP1B and reduced BDNF, we then examined if PCP may alter Akt/GSK3β signalling 
in the hypothalamic cells. After 3 hours of PCP treatment, both low dose and high dose 
of PCP reduced the Akt
Ser473
 phosphorylation, while only high dose of PCP significantly 
reduced GSK3β
Ser9
 phosphorylation (Fig.4f). After 48-h PCP treatment, both low and 
high dose of PCP reduced Akt phosphorylation (1 µM: 45%; 25 µM: 50%) and 
inhibited GSK3β phosphorylation (1 µM: 35%; 25 µM: 45%) (Fig.4g). Following the 
upregulation of PTP1B and reduction of BDNF-Akt/GSK signalling, the effect of PCP 
on the synaptic protein synaptophysin (SYN) as synaptogenesis marker was further 
examined in the primary hypothalamic neurons. Both SYN immunoreactivity and 
mRNA levels were significantly reduced by 50% and 50% after 25 µM PCP treatment 
for 48 hours (Fig.4h, 4i, and 4j). The SYN mRNA level was reduced by 40% after 3 
hours of PCP treatment (Fig.4j).  
Lupeol, PTP1B allosteric inhibitor, prevents PCP-induced reduction of BDNF-
Akt/GSK3β signalling and SYN expression 
Recently, PTP1B has been is revealed as a novel regulator of central BDNF signalling 
(Ozek et al., 2014). PTP1B inhibits BDNF–mediated signalling which is a major 
regulator of Akt/GSK3β signalling pathway (Kitagishi et al., 2012). To investigate 
whether inhibition of PTP1B could improve BDNF downstream signalling related to 
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synaptogenesis, PTP1B allosteric inhibitor Lupeol was used to examine its effects in 
prevention of PCP attenuated BDNF signalling in regulation of SYN. We and other 
group have confirmed that lupeol is PTP1B specific allosteric inhibitor (Na et al., 2009, 
Jin et al., 2016). Based on our previous study (Jin et al., 2016), we applied 50µM lupeol 
to hypothalamic cells for 24 hours following 25µM PCP administration for 48 hours. 
Lupeol significantly prevented PCP-induced PTP1B (Fig.5a). Simultaneously, Lupeol 
reversed PCP-induced decrease of JAK2 phosphorylation by 3 fold (Fig.5a). Also, 
Lupeol prevented PCP-reduced BDNF and Akt and GSK3β phosphorylations (Fig.5a 
and 5b). In addition, to investigate the effect of PTP1B inhibition on the synaptogenesis, 
the SYN immunoreactivity was examined in MAP2-positive primary cultured 
hypothalamic neurons treated with 50µM lupeol for 24 hours following 25µM PCP 
exposure for 24 hours. Lupeol treatment performed a 1.8-fold increase of SYN 
immunoreactivity compared to the control group treated with PCP only (Fig.5c and 
Fig.5d). We showed that Lupeol’s inhibition on PTP1B improved synaptogenesis. 
Lupeol facilitates olanzapine to reverse PCP-induced alterations and prevent 
olanzapine-induced NPY level. 
Olanzapine is known to prevent some PCP-induced behaviour changes while the 
mechanism is still largely unknown (Patil et al., 2007). In the present study, we 
investigated if olanzapine or combination of lupeol and olanzapine could prevent PCP 
induced over-expression of PTP1B and its related downregulation of BDNF and 
impairment of Akt/GSK3β pathway. 5µM olanzapine with or without 10µM and 50µM 
lupeol were administrated to hypothalamic cell line which had been exposed to 25µM 
PCP for 48 hours. PTP1B protein level was not significantly decreased by olanzapine 
treatment and olanzapine with low dosage of lupeol (10µM). However the co-treatment 
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of olanzapine and high dosage of lupeol (50µM) significantly inhibited PTP1B 
expression (Fig.6a). Olanzapine significantly increased pAkt and pGSK3β with minor 
improvement on pJAK2 and BDNF protein level (Fig.6b and 6c). Co-treatment of high 
dosage of lupeol and olanzapine further increased pJAK2, BDNF, pAkt and pGSK3β 
compared with olanzapine treatment (Fig.6b and 6c), suggesting lupeol improves 
olanzapine’s effect on the enhancement of leptin signalling pJAK2, the increase of 
BDNF and Akt/GSK3β pathway activation. Moreover, Olanzapine has been found to 
induce weight gain and elevate orexigenic neurotransmitter,  neuropeptide Y (NPY) 
mRNA level (Weston-Green et al., 2012). Here we measured effects of olanzapine and 
lupeol on regulating NPY level using NPY/GFP neurons. There is a 1.4-fold increase of 
NPY level in olanzapine treatment however the co-treatment of lupeol and olanzapine 
prevented olanzapine-induced NPY level (Fig.6d). Therefore, a combination therapy of 
olanzapine with lupeol, a PTP1B allosteric inhibitor, may offer a new strategy for the 
prevention and treatment of schizophrenia pathology with reduced side effects such as 
weight gain. 
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Discussions 
This study showed that NMDA and NR2B receptor antagonists (PCP and ifenprodil) 
significantly increased PTP1B expression in the hypothalamic neurons in a dose- and 
time-manner. Previous study reported that PTP1B expression was decreased in an 
oxovanadium complex of glutamic acid suggesting possible glutamate NMDAR 
involvement (Lu et al., 2010). One previous study found that NMDA receptor didn’t 
form complex with PTP1B based on a proteomic screening of NMDA receptor-
adhesion protein, suggesting that NMDA receptor in suppression of PTP1B may not via 
direct interaction. On the other hand, the authors suggested that the undetected NMDA-
PTP1B complex might be due to comigration heavy chain during immunoblotting 
experiments (Husi et al., 2000). Therefore the relation between NMDA receptor and 
PTP1B remains unclear. Further research is required to address if there is possible direct 
relationship between NMDAR and PTP1B. PCP is a non-competitive NMDA 
antagonist, which inhibits both NR2A and NR2B subunit with poor selectivity (Paoletti 
and Neyton, 2007). It was interesting that in the present study, we found that only 
application of ifenprodil, but not PEAQX, increased PTP1B expression in the 
hypothalamic neurons, suggesting that NR2B antagonism increased PTP1B. 
Furthermore, there was a negative relationship between the NR2B phosphorylation and 
PTP1B expression in Nrg1 KO mice which supported our finding that NR2B 
downregulated PTP1B. Both NR2B deficient and NRG1 gene mutation contribute to the 
risk of developing schizophrenia (Stefansson et al., 2002, Bjarnadottir et al., 2007). 
Furthermore, recent studies have showed that Nrg1-ErbB4 signalling is required for 
NR2B phosphorylation and TrkB interacts with ErbB4 to modulate Nrg1-induced 
NR2B phosphorylation (Pandya and Pillai, 2014, Zhang et al., 2016). Interestingly, 
PTP1B inhibits TrkB and therefore disturbs Nrg1-induced NR2B phosphorylation 
` 
87 
 
(Pandya and Pillai, 2014), implicating a feedback loop between NR2B 
dephosphorylation and PTP1B increase. Here, we showed that PCP was not capable to 
increase PTP1B in Nrg1 KO mice. It could be because NR2B phosphorylation has been 
inhibited by an increased PTP1B in Nrg1 KO mice. On the other hand, Fyn appears to 
play an important role in facilitating NR2B phosphorylation (Bjarnadottir et al., 2007, 
Zhang et al., 2016). Fyn belongs to Src family which has a close link to NMDAR 
function and scizhophrenia (Pitcher et al., 2011). PTP1B has been revealed to physically 
interact Src in intact cells and modulate Src activation (Monteleone et al., 2012). It will 
be interesting to investigate the relation of PTP1B and Src contributing to schizophrenia 
and relative treatment in the future study. Overall, the findings from the present study 
showed that PTP1B was elevated by NMDA receptor blockade and NR2B antagonist 
and in Nrg1 KO mice, from which all had NR2B downregulation. Therefore, our 
findings indicated that PTP1B is an important mediator contributing to NMDA receptor 
hypofunction induced by schizophrenia mimetic drug PCP.  
Leptin is known to stimulate neurite outgrowth, synaptogenesis and synaptic plasticity 
as well as to improve learning and memory (Li et al., 2002, Bouret et al., 2004, Pinto et 
al., 2004, Farr et al., 2006). Moreover, previous studies have reported that leptin 
exclusively improves NMDA receptor-regulated synaptic transmission including 
induction of long-term potentiation (Shanley et al., 2001, Harvey et al., 2005, Harvey, 
2007), indicating that leptin signalling is capable of improving NMDA-mediated 
signalling pathway. The present study showed that NMDA receptor antagonism 
increased PTP1B which affected hypothalamic leptin signalling, indicating the 
interactions between NMDA receptor and leptin signalling pathways. Leptin signalling 
is featured by activated JAK2/STAT3 pathway. JAK2/STAT3 plays a key role in 
central nerve system involved in the regulation of synaptic plasticity (Nicolas et al., 
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2013) (Nicolas et al., 2012), promoting nerve cell proliferation (Mangoura et al., 2000) 
and regulation of energy homeostasis (Villanueva and Myers, 2008). Previous study has 
shown that PTP1B inhibits leptin signalling through attenuating JAK2/STAT3 pathway 
(Zabolotny et al., 2002). We showed that NMDA receptor/NR2B antagonism increased 
PTP1B that could lead to a decreased hypothalamic leptin signalling including pJAK2 
and pSTAT3. 
A number of studies have reported that PCP decreases BDNF protein and mRNA level 
(Snigdha et al., 2011, Adachi et al., 2013, Katanuma et al., 2014, Zhang et al., 2016). 
BDNF is an important regulator of synaptic transmission and neural plasticity (Huang 
and Reichardt, 2001). Reduction of BDNF protein and BDNF mRNA level has been 
reported in the brain of schizophrenia and other mental illness (Weickert et al., 2003, 
Weickert et al., 2005, Favalli et al., 2012). Previous study showed that PTP1B 
suppresses hypothalamic BDNF and TrkB signalling (Ozek et al., 2014, Krishnan et al., 
2015). In agreement with their study, the present study showed that PCP decreased 
BDNF-pAkt-pGSK3β signalling accompanied by an increased PTP1B. It is known that 
pAkt/pGSK3β improves synaptogenesis and neurite outgrowth (Kitagishi et al., 2012, 
Smillie et al., 2013). For example, pAkt facilitates dendritic spine protein involved in 
working memory formation (Emamian et al., 2004). GSK3β has abundant expression in 
neurons during brain development and is related to neurite outgrowth and synapse 
formation (Leroy and Brion, 1999). Indeed, the present study showed that blockade of 
NMDA receptor decreased SYN which was prevented by Lupeol. In the present study, 
we found that BDNF was decreased when PTP1B was increased by NMDAR blockade. 
In contrast, when PTP1B was inhibited by lupeol, the downregulation of BDNF 
expression was prevented, indicating a negative regulatory mechanism between PTP1B 
and BDNF. Clearly, PTP1B inhibitor lupeol was capable of preventing a 
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downregulation of BDNF via inhibiting PTP1B. These findings suggest that 
overexpression of PTP1B may contribute to NMDA hypofunction in reduction of 
synaptogenesis via lowering BDNF. While the mechanism of NMDA receptor blockade 
decreases BDNF is not known. One possibility is directly related to NMDAR-PSD95-
Nrg1 signalling to influence BDNF or via a disinhibition effect of PTP1B on 
JAK2/STAT3 (Fig.7).  
In this study, olanzapine alone did not prevent PCP-induced overexpression of PTP1B 
and reduction of leptin downstream JAK2 and BDNF. Lupeol is a PTP1B allosteric 
inhibitor (Na et al., 2009, Jin et al., 2016). Lupeol was able to specifically target PTP1B 
allosteric site to selectively inhibit PTP1B over other phosphatases including T-cell 
protein tyrosine phosphatase (TCPTP). TCPTP shares a 74% identical sequence in its 
catalytic domain with PTP1B (Iversen et al., 2002) and they have almost 
superimposable active sites. However TCPTP has different biological functions and 
signalling pathways from PTP1B as demonstrated in mouse models (You-Ten et al., 
1997, Simoncic et al., 2002). In this study we found that PCP stimulated PTP1B mRNA 
level without affecting TCPTP mRNA level (Fig.S1), indicating the requirement to 
apply PTP1B inhibitor with selectivity. We showed that a combined treatment of 
olanzapine and lupeol, completely blocked PCP-induced PTP1B overexpression and 
reductions of pJAK2 and BDNF and reduced pAkt/pGSK3β signalling. Therefore, we 
showed that lupeol improved antipsychotic drug olanzapine’s effect in the prevention of 
the PCP induced neuronal changes. This study suggests that PTP1B may play a 
significant role in psychotomimetic drug induced neuropathology and possible 
psychosis. PTP1B inhibition may be a new strategy to improve olanzapine’s therapeutic 
efficacy. Furthermore, clinical studies have indicated that obesity is highly prevalent 
among patients with schizophrenia (Elman et al., 2006). Olanzapine and other second 
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generation of antipsychotics have been reported to increase prevalence of weight gain 
side-effects (Cohn et al., 2004, McEvoy et al., 2005, Haupt, 2006, Meltzer et al., 2008). 
Recent study has revealed the interactions between olanzapine-induced weight gain and 
an elevated orexigenic neurotransmitter, neuropeptide Y (NPY) mRNA level (Weston-
Green et al., 2012). Hypothalamic PTP1B inhibition prevents weight gain and decrease 
adiposity. We further measured effects of olanzapine and lupeol on regulating NPY 
level using NPY/GFP neurons. We demonstrated 1.4-fold increase of NPY level in 
olanzapine treatment. Importantly, lupeol treatment prevented olanzapine-induced NPY 
level (Fig.6d). Therefore, co-treatment of PTP1B inhibitor, lupeol with olanzapine may 
prevent antipsychotic induced weight gain. Considering PTP1B contributes to obesity 
development, co-treatment of antipsychotic with PTP1B inhibitors may be a potential 
treatment plan. 
In conclusion, this study has demonstrated that NMDA receptor blockade significantly 
increased PTP1B expression, which is associated with downregulation of NR2B 
phosphorylation. Increased PTP1B attenuated leptin signalling and leptin-mediated 
BDNF expression through a downregulation pJAK2/pSTAT3 signalling. Furthermore, 
an increased PTP1B decreased BDNF expression, and impaired BDNF-mediated 
pAkt/pGSK3β pathway and finally suppression of synaptophysin. When we applied a 
PTP1B allosteric inhibitor, lupeol significantly reduced PTP1B expression and 
prevented the PCP-induced alterations. Lupeol enhanced antipsychotic drug 
olanzapine’s effect to prevent increased PTP1B and decreased BDNF expression. 
Therefore, PTP1B inhibition may be used as a new treatment to improve therapeutic 
efficacy and prevent the obesity induced by antipsychotics.  
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Methods and Materials: 
Primary culture of wide type and Nrg1 -/+ mouse hypothalamic neurons. Primary 
hypothalamic cell cultures from hypothalamic tissues of postnatal day 0 (PN0) wild-
type (WT) and Neuregulin-1 (NRG1)-knockout (KO) C57BL/6 mice were prepared 
based on previous literature (Hilgenberg and Smith, 2007). The procedures on animals 
were approved by the Animal Ethics Committee, University of Wollongong, NSW, 
Australia, and carried out in accordance with the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes. The culture condition was adapted 
according to Johns Hopkins online protocol (Medicine, 2015). The culture medium was 
composed of NeuroBasal medium with additive B27 and extra glucose and glutamine. 
Neurons were plated at either a final density of 1.5×10
5
 cells per cm
2
 onto Poly-D-
Lysine-coated coverslips for immunofluorescence imaging (G400-13, ProSciTech) or a 
final density of 5×10
5
 cells per cm
2
 into Poly-D-Lysine-coated 12-well cell culture plate 
for collecting protein or RNA, and maintained at 37°C with 5% CO2. At DIV 10, 25µM 
PCP (P3209, Sigma-Aldrich) was applied to neurons for 3h and 48h. To investigate the 
effect of PCP on leptin signalling, 100 nM leptin (#450-31-5000, PeproTech) was 
applied to neurons after PCP stimulations. 
Immunofluorescence and image analysis. For immunochemical staining, neurons 
were fixed with 4% paraformaldehyde in Dulbecco's PBS for 30 min at room 
temperature. The samples were further incubated with 100% methanol for 10 min in -
20°C, and blocked with 5% donkey serum in PBST for 1 hr at 37 °C. Then, anti-PTP1B 
antibody (SAB1306060, Sigma-Aldrich), anti-BDNF antibody (SC-20981, Santa-Cruz), 
anti-SYN antibody (701503, Life Technnology) and anti-MAP2 antibody (M9942, 
Sigma-Aldrich) were applied overnight at 4°C. PTP1B, SYN and BDNF were 
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visualised with isotype-specific donkey anti-rabbit IgG (H+L) secondary antibody 
conjugated with Alexa Fluor 488. MAP2 was visualised by donkey anti-mouse IgG 
(H+L) secondary antibody conjugated to Alexa Fluor 594. The concentrations of 
antibodies were applied following manufacturer’s manuals. A confocal microscope 
(Leica-TCS-SP5 Advanced System, Leica Microsystem) was used to obtain images. 
Software Image J. 10 (http://rsbweb.nih.gov/ij/download.html) was applied to quantify 
the immunoreactivity based on from 5 independent culture wells.  
Quantitative PCR. Quantitative real-time PCR (qRT-PCR) was performed as 
previously described (Yu et al., 2013b). At DIV 10, administration of 25µM PCP 
(P3209, Sigma-Aldrich) was applied to neurons for 3 and 48 hours. Neurons were 
collected for RNA extraction via Aurum
TM
 Total RNA Mini Kit (7326820, Bio-Rad 
Laboratories) and reversed to cDNA by using Applied Biosystems
TM
 High Capacity 
cDNA Reverse Transcription Kit (4368814, Life Technology). Real-time PCR was then 
performed via SensiFAST
TM
 SYBR No-ROX Kit (BIO-98005, Bioline). The mRNA 
expression levels of PTP1B (Forward: TGGCCTGACTTTGGAGTCCC; Reverse:  
CTCCAGTGTGCGTTTGGGTG.), SYN (Forward: 
GAACAAGTACCGAGAGAACAACAA; Reverse: GGTCAGTGGCCATCT 
TCACA.), BDNF (Forward: GGGTCACAGCGGCAGATAAA; Reverse: 
GCCTTTGGATA CCGGGACTT.) and TCPTP (Forward: 
AGAGTGGCCAAGTTTCCAG; Reverse: CACA CCATGAGCCAGAAATG.) were 
normalised to γ-actin (Forward: GCTAACAGAGAGAA GATGACG; Reverse: 
CAGATGCATACAAGGACAGC), which served as the internal control. Experiments 
were performed in triplicate. 
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Mouse hypothalamic cell culture.  The mouse hypothalamic A-59 neurons (mHypoA-
59 neurons, CELLutions) were grown in monolayer in Dulbecco’s modified Eagle 
medium (DMEM) (D5796, Sigma-Aldrich) with 10% foetal bovine serum (FBS) 
(SFBS-F, Bovogen Biologic.Pty.Ltd) and 1% penicillin/streptomycin. Hypothalamic 
cells were maintained at 37C with 5% CO2. To expose the role of PCP in hypothalamic 
cell line, administration of 1µM PCP or 25µM PCP (P3209, Sigma-Aldrich) were 
applied to neurons for 3 and 48 hours. To investigate the NMDA receptor subunit 
involved in PTP1B expression, both 5µM and 50µM NR2A antagonist Peaqx (I2892, 
Sigma-Aldrich) and NR2B antagonist ifenprodil (P1999, Sigma-Aldrich) were 
administrated to cell line for 24 and 48 hours. To reveal the signalling pathway involved 
in PCP induced leptin signalling dysfunction, 100nM leptin (450-31-5000, PeproTech) 
was administrated to cells for 4 hours after PCP 3 and 48 hours. Prior to leptin 
treatment, the cell culture medium was replaced with serum free medium for 4 hours. 
To investigate the effect of PTP1B inhibition in hypothalamic cells, 10µM and 50µM 
PTP1B inhibitor Lupeol (L5632, Sigma-Aldrich) and 5µM atypical antipsychotic 
Olanzapine (O1141, Sigma-Aldrich) were dissolved in Dimethyl sulfoxide (DMSO), 
then diluted in sterile water, and mixed with serum free cell culture medium. Cells were 
exposed to 25µM PCP for 48 hours and replaced with serum free cell culture medium, 
then lupeol, olanzapine and co-treatment were applied to cells for 24 hours individually. 
To examine the influence of PTP1B inhibition on neurite synaptogenesis, 50µM lupeol 
was administrated to primary hypothalamic neurons which have been treated by 25µM 
PCP for 24 hours, and then co-incubated for another 24 hours. The DMSO 
concentration was controlled below 0.5%.  
Western blot analysis: Detailed protocols were described in our previous study (Yu et 
al., 2013b), primary cultured hypothalamic neurons and mHypo neurons were washed 
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with ice-cold PBS and lysed in NP-40 lysis buffer (FNN0021, Invitrogen) containing a 
protease inhibitor cocktail, beta-glycerophosphate and phenylmethanesulfonyl fluoride 
(PMSF) (Sigma- Aldrich). Protein concentrations were determined using the DC
TM
 
Protein Assay kit (5000121, Bio-Rad Laboratories). Equal amounts of protein were 
separated on 4-20% Criterion
TM
 TGX 
TM
 Precast Gels (567-1095, Bio-Rad 
Laboratories) using SDS-PAGE. Following electrophoresis (120 V for 1.5 h), the 
proteins were transferred to polyvinylidene difluoride membranes (100 V for 1 hr). 
Membranes were blocked in 5% bovine serum albumin (BSA) or 5% skim milk 
depending on the primary antibodies used, followed by incubation with the primary 
antibodies anti-PTP1B (SAB1306060, Sigma-Aldrich), anti-BDNF antibody (SC-
20981, Santa-Cruz), pNR2B
Tyr1472
 (4208S, Cell Signalling Technology), NR2B (4207S, 
Cell Signalling Technology), anti-pAkt
Ser473 
(D9E, Cell Signalling Technology), anti-
Akt (SC8312, Cell Signalling Technology), anti-pGSK3β
Ser9
 (5B3, Cell Signalling 
Technology), GSK3β (D75D3, Cell Signalling Technology), pJAK2
Tyr1007/1008
 (C80C3, 
Cell Signalling Technology), JAK2 (D2E12, Cell Signalling Technology), 
pSTAT3
Tyr705
 (D3A7, Cell Signalling Technology), STAT3 (79D7, Cell Signalling 
Technology) and anti-actin (MAB1501, Millipore) in 1% BSA or 1% skim milk 
overnight at 4C. Following washes (3×5 min) in Tris Buffered Saline+0.1% Tween 20, 
membranes were incubated with respective secondary antibodies for 1 hr at 25C. Blots 
were visualised using Amersham
TM
 ECL
TM
 Detection Reagents (RPN2106, Ge 
Healthcare) and exposed in dark room. The bands corresponding to the proteins of 
interest were scanned and analysed using the automatic imaging analysis system 
Quantity One (Bio-Rad Laboratories). All quantitative analyses were normalised to 
actin. 
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Neuron Neuropeptide Y (NPY) detection: The mouse hypothalamic NPY/GFP 
neurons (mHypoA-NPY/GFP neurons, CELLutions) were cultured in the 96-well plate 
in the same incubation condition as mHypoA-59 neurons. 5µM olanzapine, 50µM 
lupeol and co-treatment of olanzapine and lupeol were applied to neurons. After 6h 
treatment, discard culture medium and measure neuron NPY-bound GFP 
immunoactivity using FlexStation 3 (Molecular Devices). Wavelength of detection is 
set from 488 nm to 510 nm, cutoff at 495 nm.   
Statistical analysis: Data from the immunofluorescence imaging, RT-PCR analysis and 
western blot were analysed using the SPSS 19 statistical package (SPSS, Chicago, IL). 
One-way analysis of variance (ANOVA) was applied in all experiments followed by the 
post-hoc Tukey-Kramer honestly significant difference (HSD) test. 
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Figure Captions: 
Fig.1: PTP1B expression stimulated by PCP in mouse hypothalamic A-59 (mHypo) 
neurons and primary hypothalamic neurons. a): 25µM PCP for 3 hours treatment 
significantly increased PTP1B expression in mHypo neurons. b): Both 1µM and 25µM 
PCP for 48 hours increased PTP1B expression (+30% and +60%) (n=6). c and 
d):PTP1B immunoreactivity was significantly increased in primary cultured 
hypothalamic neurons treated with 25µM PCP for 48 hours (n=10).  e): The level of 
PTP1B mRNA level was significantly increased after 3 and 48 hours exposure to 25µM 
PCP (n=6). Mean ± SEM, Scale bar =25µm, *p<0.05, **p<0.01. 
 
Fig.2: PTP1B was induced by decreased pNR2B. a): PTP1B expression was 
significantly increased by 50µM ifenprodil but not 5µM ifenprodil for 24h treatment (a) 
(n=6). b): When ifenprodil treatment was prolonged to 48h, low dosage (5µM) 
ifenprodil showed increased PTP1B expression as well (n=6).  c and d): NR2A 
antagonist Peaqx did not change PTP1B expression when 5µM and 50µM dose were 
used for 24 and 48 hours (n=6). e): Phosphorylated NR2B was significantly lower in the 
Nrg1 KO hypothalamic neurons (n=6). f and g): PTP1B expression was significantly 
higher in Nrg1 KO mice than wild type mice and 25µM PCP had no effect on PTP1B 
expression in Nrg1 KO mice (n=10). Mean ± SEM, Scale bar =10µm, *p<0.05, 
**p<0.01. 
 
Fig.3: PCP reduced leptin induced elevation of BDNF, pJAK2 and pSTST3 in the 
hypothalamic neurons. a): Leptin increased JAK2 and STAT3 phosphorylations, 
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which were affected by PCP examined in both 3 and 48 hours. b and c): Leptin 
increased BDNF protein (n=10) and mRNA (d) (n=6) level but were inhibited by PCP. 
Mean ± SEM, Scale bar =25 µm, *p<0.05, **p<0.01.  
 
Fig.4: PCP treatment reduced BDNF level and BDNF-mediated Akt/GSK3β 
pathway, leading to decreased synaptophysin (SYN). PCP decreased BDNF 
expression in mHypo neurons in 3 (a) and 48 (b) hours (n=6). c and d): PCP decreased 
BDNF protein (n=10) and mRNA (e) (n=6) level in 3 and 48 hours in primary cultured 
hypothalamic neurons. PCP reduced Akt and GSK3β phosphorylation in both 3 (f) and 
48 (g) hours in mHypo neurons (n=6). h and i): PCP significantly decreased SYN level 
in 48 hours (n=10). j): Both PCP 3h and 48h treatment reduced SYN mRNA (n=6). 
Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01.  
 
Fig.5: Lupeol prevented PCP-induced changes in PTP1B, pJAK2, BDNF, pAkt, 
pGSK3β and synaptophysin. a): PTP1B allosteric inhibitor lupeol reversed PCP-
induced elevation of PTP1B, and down-regulation of pJAK2 and BDNF in 
hypothalamic neurons (n=6). b): Lupeol reversed PCP-induced reduction of pAkt and 
pGSK3β (n=6). c and d): Lupeol prevented SYN downregulation induced by PCP 
(n=10). Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01.  
 
Fig.6: Lupeol improved olanzapine treatment effects and decreased olanzapine-
induced NPY. a): Olanzapine could not inhibit PCP-induced increase of PTP1B which 
was however prevented by a combined olanzapine and lupeol treatment (n=6). b and c): 
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A combined olanzapine and lupeol treatment showed improved efficacy to increase 
pJAK2, BDNF, pAkt and pGSK3β compared to olanzapine treatment (n=6). d): 
Olanzapine treatment showed 1.4-fold increase of NPY which was inhibited with the 
application of lupeol (n=10). Mean ± SEM, Scale bar =10µm, *p<0.05, **p<0.01, 
***p<0.001.  
Fig.7: PTP1B mediates NMDA receptor/NR2B antagonism induced impairment of 
synaptogenesis. NR2B dysfunction induced by PCP or Nrg1 KO stimulated PTP1B. 
Enhanced PTP1B directly reduced pJAK2, leading to impaired leptin signalling and 
decreased pSTAT3 which further inhibited BDNF level, pAkt and pGSK3β expression 
on synaptogenesis. Lupeol is a PTP1B allosteric inhibitor which prevented these 
changes and restored altered BDNF and pAkt and pGSK3β pathway to improve 
synaptogenesis.  
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Fig.S2: PCP significantly increased PTP1B mRNA level but not TCPTP mRNA level. a: 
RT-PCR analysis showed that neither PCP 3-h nor 48-h treatment increased TCPTP 
mRNA expression (n=6). B): Both PCP 3-h and 48-h treatments increased PTP1B but 
not TCPTP mRNA expression following leptin stimulation (n=6). Data are presented as 
mean ± SEM, *p<0.05, **p<0.01. 
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Fig.S3: a): 25 µM PCP for 48h inhibited NR2B phosphorylation. b): 5 µM Ifenprodil 
for 48h reduced NR2B phosphorylation. Data are presented as mean ± SEM (n=6). 
*p<0.05, **p<0.01. 
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Chapter Four 
A label-free and high-throughput separation of neuron and glial cells using an inertial 
microfluidic platform 
 
Reprinted from Biomicrofluidics, Copyright (2016), with permission from American 
Institute of Physics (See Appendix A) 
 
Available at: http://scitation.aip.org/content/aip/journal/bmf/10/3/10.1063/1.4949770 
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Chapter Five 
5.1 Overall Discussion 
Increasing evidence has confirmed PTP1B as a promising therapeutic target for treating 
obesity. However, PTP1B traditional inhibitors are targeting the PTP1B active site 
which is very similar to other PTPs, causing off-target effects and reduced 
bioavailability. Allosteric inhibition thus becomes a promising alternative strategy to 
develop selective PTP1B inhibitors. Previous structural and biochemical studies have 
unveiled the allosteric binding site, and allosteric inhibition aims to disturb PTP1B 
conformational transition during catalysis and therefore inhibits PTP1B activity 
(Wiesmann et al., 2004).  
In Chapter 2, lupeol and lupane triterpenes including lupenone, betulin and betulinic 
acid are identified as new PTP1B allosteric inhibitors. Using molecular docking, lupane 
triterpenes were demonstrated to bind to the PTP1B allosteric site. The performance of 
molecular dynamics simulations showed the stability of the protein-ligand complex and 
elucidated the interactions between lupane triterpenes and the PTP1B binding site, 
indicating the important role of helix 𝛼7 and several hydrophobic residues in the 
binding mode. Moreover, the pentacyclic structure in lupane triterpenes is confirmed as 
the main contributor to allosteric binding, while the different formation of hydrogen 
bonds leads to variation of electrostatic forces, which explains the distinction between 
binding affinity and inhibitory activity among lupane triterpenes. Further enzymatic 
assays showed that lupane triterpenes specifically inhibited PTP1B over TCPTP. In 
addition, molecular docking of lupane triterpenes targeting TCPTP was applied. It 
appeared lupane triterpenes were not binding to TCPTP in the region which is 
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equivalent to the allosteric site in PTP1B. Thus the less-conserved PTP1B allosteric site 
is an ideal target for lupane triterpenes to inhibit PTP1B activity. Finally, lupane 
triterpenes showed significant PTP1B activity inhibition effects in neuronal cells with 
positive bioavailability and less toxicity. 
Importantly, there was demonstrated relative consistency between computed data and 
experimental results in this work. For example, results from binding free energy 
calculations showed that betulinic acid had a better inhibitory effect than lupeol. 
Betulinic acid is able to form stronger hydrogen bonding interactions than lupeol and 
the other two lupane triterpenes, providing stronger electrostatic force, which is 
consistent with the experimental IC50 data. Therefore, this computational modelling is 
reliable to compare the inhibitory effects between lupane triterpenes derivatives. The 
structural difference between lupeol and betulinic acid lies in the R2 group which 
strongly enhance the inhibitory effect of betulinic acid. Considering that the non-polar 
pentacyclic structure of lupane triterpenes is the premise for binding to the less polar 
allosteric site, modification of the polar functional group is an alternative choice. 
Currently all lupane triterpenes are difficult to dissolve in water which limits drug 
administration, therefore further modification could be focused on increasing 
hydrophilicity. However, such modifications need careful investigation since this will 
affect their pharmacokinetic properties. As an important negative regulator modulating 
food intake, body weight gain and energy homeostasis, PTP1B is an attractive drug 
target for preventing and treating obesity and its associated metabolic syndromes 
including diabetes. This study provides a reliable PTP1B allosteric inhibitor discovery 
platform, with combined computational modelling and biological assays, to develop 
new PTP1B allosteric inhibitors including lupane triterpenes derivatives with enhanced 
potency, selectivity and bioavailability.  
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Recent studies have revealed the role of PTP1B in blocking BDNF-mediated signalling 
and causing impaired neurogenesis in several neurological diseases (Krishnan et al., 
2015). Given the prevalence of BDNF reduction in schizophrenia patients, it is crucial 
to investigate whether PTP1B is involved in impaired neurogenesis in schizophrenia. In 
Chapter 3, PTP1B level is significantly induced in two schizophrenia-like models, PCP-
treated model and NRG1 KO mouse model, both well-established models to mimic the 
schizophrenia symptoms in humans. PCP, as a well-recognized non-selective NMDAR 
antagonist, binds equally to NR2A and NR2B subunits (Paoletti and Neyton, 2007).  To 
further investigate the mechanism of PCP induced PTP1B, NR2A specific antagonist 
PEAQX and NR2B specific antagonist ifenprodil were tested to stimulate PTP1B 
expression. Results showed that only ifenprodil treatment with reduced NR2B 
phosphorylation was able to increase PTP1B level. Moreover, the reduction of NR2B 
phosphorylation and enhanced PTP1B expression was also disclosed in Nrg1 KO mice 
which supported our finding that NR2B downregulated PTP1B. On the other hand, 
Nrg1-ErbB4 signalling is required for NR2B phosphorylation (Bjarnadottir et al., 2007). 
A recent study has reported that PTP1B inhibits TrkB, a crucial regulator which 
interacts with ErbB4 to modulate Nrg1-induced NR2B phosphorylation (Pandya and 
Pillai, 2014), indicating that NR2B dephosphorylation induced PTP1B which further 
inhibited Nrg1-induced NR2B phosphorylation as a negative feedback. Both NR2B 
deficient and NRG1 gene mutation are important contributors to the risk of 
schizophrenia (Stefansson et al., 2002, Bjarnadottir et al., 2007), and PTP1B appears to 
be a crucial factor in the psychopathology. 
Moreover, the reduction of BDNF and BDNF-mediated Akt/GSK3β signalling leads to 
impaired neurogenesis and synaptogenesis, which has been demonstrated in 
schizophrenia patients (Weickert et al., 2003, Weickert et al., 2005, Favalli et al., 2012) 
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as well as PCP-treated models (Snigdha et al., 2011, Adachi et al., 2013, Katanuma et 
al., 2014, Zhang et al., 2016). However the mechanism remains unclear. This study 
proposes that PTP1B regulates the BDNF level and BDNF-mediated Akt/GSK3β 
signalling in the PCP-treated model. PTP1B has been reported to inhibit TrkB, which is 
the transmembrane receptor of BDNF (Ozek et al., 2014, Krishnan et al., 2015), and 
modulates BDNF-mediated Akt/GSK3β signalling. In Chapter 3, elevated PTP1B 
suppressed pAkt and pGSK3β, and inhibition of PTP1B restored Akt/GSK3β signalling 
and downstream synaptogenesis. Therefore, PTP1B is able to block Akt/GSK3β 
signalling and results in impaired neurogenesis and synaptogenesis. This study also 
revealed that PTP1B directly modulates BDNF level through leptin-mediated 
JAK2/STAT3 signalling. Leptin stimulates BDNF expression in the dendrites of 
hypothalamic neurons (Liao et al., 2012), as well as BDNF mRNA in the hypothalamic 
region (Komori et al., 2006). In Chapter 2, leptin signalling has been confirmed to be 
inhibited by PCP-induced PTP1B, which directly dephosphorylated JAK2 and blocked 
leptin-mediated JAK2/STAT3 signalling, leading to the BDNF reduction. Previous 
studies have suggested that leptin exclusively improves NMDA receptor-regulated 
synaptic transmission such as the induction of long-term potentiation (Shanley et al., 
2001, Harvey et al., 2005, Harvey, 2007), indicating that leptin signalling is capable of 
improving the NMDA-mediated signalling pathway. The present study showed that 
NMDA receptor antagonism stimulated PTP1B which affected hypothalamic leptin 
signalling, indicating the reciprocal interactions between NMDA receptor and leptin 
signalling pathways. Considering the important role of leptin signalling in controlling 
food intake, weight gain and energy homeostasis, the disturbed leptin function in the 
PCP-treated model may explain the prevalence of obesity in schizophrenia patients. 
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Based on the results from Chapter 2, lupeol was identified as a PTP1B allosteric 
inhibitor which inhibits PTP1B with potency and selectivity over TCPTP. It is worth 
mentioning that in the PCP-treated model, only PTP1B was increased but not TCPTP, 
suggesting PTP1B selective inhibition is required for treatment. Therefore, lupeol was 
applied to the PCP-treated model with or without olanzapine treatment, to investigate 
the co-treatment effect of PTP1B inhibition and olanzapine. Olanzapine showed no 
effects on preventing PCP-induced overexpression of PTP1B and reduction of leptin 
downstream JAK2 and BDNF although BDNF-mediated Akt/GSK3β signalling was 
restored. However, lupeol inhibited PCP-induced PTP1B expression and the co-
treatment of lupeol and olanzapine confirmed improved effects in reversing PCP-
induced alterations including reduction of BDNF, Akt/GSK3β signalling, and decreased 
synaptophysin, mainly due to the PTP1B inhibition-related restoration of JAK2/STAT3 
signalling, which stimulated BDNF expression. Importantly, a recent study has shown 
the interactions between olanzapine-induced weight gain and an elevated orexigenic 
neurotransmitter,  neuropeptide Y (NPY) mRNA level (Weston-Green et al., 2012). The 
co-treatment of olanzapine and lupeol managed to inhibit the olanzapine-induced NPY 
level. Therefore, co-treatment of PTP1B inhibitor, lupeol, with olanzapine may enhance 
olanzapine’s treatment efficacy and prevent olanzapine-induced weight gain. 
Interest in glia is rising due to increasing evidence supporting the important role of 
dynamic neuron–glia in neurogenesis and synaptic formation. For example, astrocyte, 
one type of glia, modulates multiple aspects of neuron growth and synaptic function 
from development through to adulthood, including involvement in synapse formation, 
as well as uptake and recycling of neurotransmitters. Recent studies also revealed 
astrocytic dysfunction in several brain disorders including schizophrenia with 
significant cognitive impairments. Astrocyte loss has been observed in the prefrontal 
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cortex which triggered neuronal damage causing cognitive impairment in the animal 
model (Lima et al., 2014). Consequently, astrocyte could have an as yet unexpected role 
in the neuron-glia interactions in the diseased brain. An improved understanding of 
astrocyte biology and function offers the potential for developing novel strategies to 
treat neurological disorders. Despite the growing realization of the importance of the 
neuron-glia relationship, we are still in the early stages of understanding the 
physiological consequences of the bidirectional communication between neurons and 
glia, mainly due to the difficulty in separating neurons and glia from the cell mixture in 
brain tissue. 
In Chapter 4, a high-throughput microfluidic platform based on an inertial microfluidic 
technique was established to separate neurons and glial cells from dissected brain tissue 
rapidly and continuously. The microfluidic platform was set up based on size-dependent 
separation due to the significant variation of cell diameters between neurons and glia. 
Larger-size cells collected from the middle outlet were characterised as neurons while 
smaller cells collected from the aside outlet were determined as glia. Immunostaining 
was applied to test the cell types and confirm the high separation effects. Collected cells 
were then incubated for downstream experiments. This method provided highly 
enriched and purified neurons and glia, compared to the traditional methods, in which 
glial cells are mixed with neurons, and each well for incubation only contains a limited 
numbers of cells of interest. Moreover, separated neurons were as healthy and 
functional as unprocessed neurons, and there was no significant variation in the growth 
and synaptogenesis of neurites caused by the inertial separation process. 
Cell sorting has been broadly applied in biological studies, however live cell sorting 
from tissue is still a challenge. Fluorescence-activated cell sorting (FACS) and 
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magnetically-activated cell sorting (MACS) have been used for sorting cells. However, 
these methods require cell labelling which is a time and labour consuming step, and 
more importantly, application of antibodies to label cells will further interfere with the 
immunochemistry analysis of target proteins of interest. Microfluidic technology has 
been introduced to perform cell sorting studies. Dielectrophoresis (DEP)-based 
microfluidic devices distinguish cells by their dielectric properties as a label-free 
technique. However these devices normally run in a batch manner and with a very 
limited throughput. Apart from DEP, another study  has reported the application of 
viscoelasticity-tuned hydrodynamic spreading to neural cell separation where the 
microfluidic device works in a continuous and label free manner (Wu et al., 2008). Such 
a device could achieve relative high viability of neural cells through separation. 
However, the flow rate (20 µl/h) and the throughput (3 ×10
4
 cells/h) are still not 
satisfactory, and therefore need further improvement. This study applied a label-free 
and high-throughput microfluidic device in which cells passed through the 
microchannel in an inertial microchip at ~1 m/s with significantly improved throughput 
of 1.188 ×10
7
 cells/h. Although the current throughput rate is still lower than FACS, this 
proposed device can be further amplified by parallelizing several microchannels to 
increase throughput capability. Importantly, the present inertial microfluidic platform is 
biocompatible, elastomeric, transparent and gas-permeable, suitable for cell incubation. 
In future studies, this device will be designed to establish a multi-functional platform 
combining separating, sorting, incubation and neurite outgrowth measurement, to 
further investigate the neuron-glia interactions and proteins of interest. For example, a 
recent study has found PTP1B in microglia contributing to neuroinflammation (Song et 
al., 2016) and neuroinflammation is strongly linked to development of neurological 
disorders including schizophrenia (Meyer, 2013). Therefore, it is of great interest to 
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discover the role of PTP1B in glial cells regulating neurite outgrowth, synaptic 
formation and neurotransmitters function in future studies, with application of the 
inertial microfluidic platform.   
5.2 Conclusion 
PTP1B has been reported to impair BDNF-mediated signalling and then inhibit neurite 
outgrowth and synaptic formation. Moreover, PTP1B blocks leptin signalling which is 
known to increase BDNF and promote neurite outgrowth. Therefore PTP1B is a 
potential drug target to reverse abnormality of BDNF-mediated neurogenesis in 
neurological disorders. In this study, lupane triterpenes, a cluster of natural products, 
were determined as novel PTP1B allosteric inhibitors which inhibit PTP1B with strong 
potency and selectivity. Lupane triterpenes inhibit psychotomimetic drug-induced 
PTP1B and reverse PTP1B-induced BDNF reduction and neurogenesis impairment, 
demonstrating that lupane triterpenes are potential drug candidates for PTP1B inhibition 
and PTP1B-related neurological disorders.  
In the present study, lupeol and other members of lupane triterpenes were demonstrated 
as PTP1B allosteric inhibitors. With the application of molecular modelling and 
biological assay, lupeol was revealed to target the PTP1B allosteric binding site to 
inhibit PTP1B with selectivity and potency. Through the investigation of lupeol 
structural properties, further structural modification was determined to discover a series 
of lupeol derivatives. 
PTP1B is identified as a new factor contributing to the psychopathology in 
schizophrenia-like models. PTP1B was found significantly increased during the 
psychotomimetic drug (phencyclidine) treatment, resulting in the decrese of leptin 
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signalling, reduction of BDNF level, attenuation of the BDNF-mediated Akt/GSK3β 
pathway and neurogenesis, suggesting PTP1B as a new drug target. 
Furthermore, the natural triterpene lupeol was applied to prevent PCP-induced PTP1B 
expression. Lupeol managed to reduce PTP1B and reversed PCP-induced 
schizophrenia-like alterations. Importantly, the combined treatment of lupeol and 
atypical antipsychotic, olanzapine, showed improved treatment efficacy and reduced 
side effects compared to individual olanzapine application, implicating PTP1B 
inhibition as a potential treatment strategy. 
Finally, to investigate the role of PTP1B in specific cell types of neurons and glia in 
future studies, an inertial microfluidic biochip was introduced to separate neurons and 
glia from mouse brain tissue for primary cell culture. This microfluidic platform was a 
high through-put device, able to separate neurons and glia with efficiency and purity, 
and there was no damage to cell viability and biological functions during the process. 
In conclusion, this PhD project determined natural compounds lupane triterpenes as new 
PTP1B allosteric inhibitors which inhibit PTP1B with high potency and selectivity. 
PTP1B was further confirmed as contributing to BDNF reduction and neurogenesis 
impairment in schizophrenia-like models, indicating PTP1B as a potential drug target. 
Application of lupane triterpene significantly improved therapeutic efficacy and 
prevented the side effects induced by antipsychotics. Finally, development of the 
microfluidic microchip will improve investigation of PTP1B in specific cell types in 
future studies. 
5.3 Recommendations for Future Research 
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1. Further characterise the interactions between lupane triterpenes and PTP1B allosteric 
site. Experimental methods including NMR and mutant protein purification 
technologies will be applied to determine the crucial amino acids in PTP1B which 
contribute to the allosteric binding mode. 
2. Chemical modifications of lupeol based on results and discussions in Chapter 2 and 
future NMR data. Apply computer-aid drug design to develop novel lupeol derivatives 
targeting PTP1B allosteric site with improved potency, selectivity and bioavailability. 
3. Application of new lupeol derivatives on neural cell cultures to improve neurite 
outgrowth, synaptic function and relative signalling pathway. 
4. Animal models will be applied in future studies to test the improved behaviour and 
cognition with the treatment of lupeol derivatives. 
5. Combination of lupeol derivatives and antipsychotic olanzapine will be administrated 
to animal models to demonstrate improved treatment efficacy with reduced side effects 
such as body weight gain. 
6. Microfluidics-based cell culture system will be established using new biocompatible 
materials and high-resolution fabrication technologies, to separate neurons and glia with 
purity and viability from brain sections. 
7. With the new established microfluidic system, PTP1B in microglia will be examined 
to determine its contributions to neuroinflammation. PTP1B in astrocyte will be 
investigated to reveal its role contributing to impaired neurite outgrowth and 
neurogenesis in neurological disorders.   
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8. The microfluidic system could be further modified to establish neuron-glia co-culture 
system, to investigate the neuron-glia interactions in neurological disorders and reveal 
the role of PTP1B involved.  
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